WO2003028724A1 - Chk1 kinase inhibitors - Google Patents

Chk1 kinase inhibitors Download PDF

Info

Publication number
WO2003028724A1
WO2003028724A1 PCT/US2002/031842 US0231842W WO03028724A1 WO 2003028724 A1 WO2003028724 A1 WO 2003028724A1 US 0231842 W US0231842 W US 0231842W WO 03028724 A1 WO03028724 A1 WO 03028724A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyrrolo
pyridin
phenyl
nicotinamide
butyramide
Prior art date
Application number
PCT/US2002/031842
Other languages
French (fr)
Inventor
Robert A. Stavenger
Jason Witherington
Derek A. Rawlings
Dennis A. Holt
George. Chan
Original Assignee
Smithkline Beecham Corporation
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation, Smithkline Beecham Plc filed Critical Smithkline Beecham Corporation
Publication of WO2003028724A1 publication Critical patent/WO2003028724A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B11/00—Diaryl- or thriarylmethane dyes
    • C09B11/04—Diaryl- or thriarylmethane dyes derived from triarylmethanes, i.e. central C-atom is substituted by amino, cyano, alkyl
    • C09B11/10—Amino derivatives of triarylmethanes
    • C09B11/24—Phthaleins containing amino groups ; Phthalanes; Fluoranes; Phthalides; Rhodamine dyes; Phthaleins having heterocyclic aryl rings; Lactone or lactame forms of triarylmethane dyes

Definitions

  • the present invention relates to damage response kinase inhibitors, especially checkpoint kinase ("chkl kinase”) inhibitors, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat various forms of cancer and hyperproliferative disorders.
  • damage response kinase inhibitors especially checkpoint kinase ("chkl kinase”) inhibitors
  • pharmaceutical compositions comprising these compounds and methods of using these compounds to treat various forms of cancer and hyperproliferative disorders.
  • the cellular response to DNA damage involves cell cycle delays, increased repair and apoptosis (Zhou and Elledge Nature 2000. 408:433-439).
  • cell cycle delays also called checkpoints
  • repair activation which provides both the opportunity and capacity for cells to repair DNA damage. It is likely that approaches abrogating these survival DNA damage responses would have significant clinical utility.
  • Chkl was linked to survival responses including checkpoints.
  • Mice lacking CHK1 die in early embryogenesis (Liu et al.Gerce & Dev. 2000 14: 1448-1459; Takai et al, Gene & Dev. 2000. 14: 1439-1447).
  • ES cells expressing a conditional CHK1 gene die of p53-independent apoptosis after loss of CHK Prior to their death, these cells become incapable of preventing mitotic entry in response to IR (Liu et al.Gene & Dev. 2000 14: 1448-1459), demonstrating that Chkl is required for the G2 DNA damage checkpoint in mammals as previously observed in other organisms.
  • Chkl prevents mitotic entry as follows. Arrest in G2 is regulated by the maintenance of inhibitory phosphorylation of Cdc2 (Nurse Cell 1997. 91: 865-867). Cdc2 dephosphorylation and activation is catalyzed by the dual specificity phosphatase Cdc25 (Morgan Nature 1995. 374: 131-134). Recent evidence indicates that part of the G2/M D ⁇ A checkpoint mechanism involves inactivation and translocation of Cdc25C into the cytoplasm. This is at least partially mediated by phosphorylation on Ser-216 in Cdc25C and its consequent binding with 14-3-3 proteins (Peng et al., Science 1997. 277: 1501-1505; Dalai et al. Mol.
  • Chkl (Sanchez et al. Science 1997. 277: 1497-1501) has been shown to phosphorylate Cdc25C at Ser- 216 in vitro. This modification is thought to maintain Cdc25C phosphorylation in cells arrested at G2/M in response to DNA damage.
  • staurosporine-like kinase inhibitors UCN-01 and SB-218078, have been shown to be potent Chkl inhibitors (Jackson et al. Cancer Res. 2000. 60: 566-572; Graves et al. J. Biol. Chem. 2000. 275: 5600-5605).
  • Chkl inhibitor In vivo, they can abrogate the G2/M checkpoint induced by DNA damaging agents and enhance the cytotoxicities of the DNA damaging agents. Thus it is likely that a specific Chkl inhibitor could be used clinically in combination treatment with coventional therapies. Since Chkl is an essential kinase for regular cell cycle (Liu et al.Gene & Dev. 2000 14: 1448-1459), it is possible that Chkl inhibitor could also be used alone in cancer therapy.
  • the present invention involves pyrolo[2,3-b]pyridine compounds represented by Formula (I) hereinbelow, pharmaceutical compositions comprising such compounds and methods of inhibiting kinase as well as specific assays to detect inhibition of chkl kinase activity.
  • the present invention provides compounds of Formula (I), hereinbelow:
  • R 1 is aryl or heteroaryl, wherein aryl or heteroaryl may optionally be substituted by one or more of group A and on any position with the exception that R 1 is not 3,4- dichlorophenyl, with the preferred substitution being 3-,4- or 5-alkoxy- or hydroxy- or amino- or hydroxymethyl- or aminomethyl- or acetamido- or aminosulfamoyl- or dimethylamino- phenyl including di- and tri-substitution or 3-thienyl, with the more preferred substitution being 4-hydroxy-3-methoxyphenyl or 3-acetamidophenyl or 3,4-dimethoxyphenyl or 4-aminophenyl or 4-aminomethylphenyl or 4- dimethylaminomethylpheny 1 ;
  • R 3 , R 4 , and R 5 are independently selected from the group consisting of hydrogen, C,_ 10 alkyl, C, .10 alkanoyl, C 2.I0 alkenyl, C 2.10 alkynyl, C 3.10 cycloalkyl, C M alkylaryl, C M alkylheterocyclyl, and C 0.6 alkylheteroaryl; or R 3 and R 4 taken together with the nitrogen to which they are attached form a ring having 3 to 7 carbon atoms optionally containing 1, 2, or 3 heteroatoms selected from nitrogen, sulfur, oxygen, or nitrogen, substituted with hydrogen, C, .6 alkyl or (CH 2 ) 0.3 aryl, wherein any of the foregoing may be optionally substituted by one or more of group C and on any position;
  • R 6 , R 7 , and R 8 are independently selected from the group consisting of hydrogen, C, . ,,, alkyl, C, .]0 alkanoyl, C 2.10 alkenyl, C 2.10 alkynyl, C 3.10 cycloalkyl, C 0.6 alkylaryl, C 0.6 alkylheterocyclyl, and C 0.6 alkylheteroaryl; or R 7 and R 8 taken together with the nitrogen to which they are attached form a ring having 3 to 7 carbon atoms optionally containing 1, 2, or 3 heteroatoms selected from nitrogen, sulfur, oxygen, or nitrogen, substituted with hydrogen, C alkyl or (CH 2 ) 0.3 aryl; R" is selected from the group consisting of C ⁇ _ 8 alkyl, C 2 .
  • R 9 is hydrogen or . 6 alkyl, wherein any of the foregoing groups are optionally substituted with one or more of group D and at any position, with the exception that
  • R 9 is not tert-butyl
  • R 10 is selected from the group consisting of hydrogen, methyl and ethyl
  • R u is selected from the group consisting of hydrogen, C j hand6 alkyl, C 2.8 alkenyl and C 3 _ 6 cycloalkyl, wherein any of the foregoing groups are optionally substituted with one or more of group D and at any position;
  • R 10 and R u taken together with the nitrogen to which they are attached may form a ring having 3 to 7 carbon atoms optionally containing 1, 2, or 3 heteroatoms selected from nitrogen, sulfur, oxygen, or nitrogen, substituted with hydrogen or C,_ 6 alkyl;
  • D is selected from the group consisting of C 6 alkyl, C 2.8 alkenyl, C 3.6 cycloalkyl,
  • OR 12 OC(O)NR 12 R 13 , NR 14 SO 2 R 12 R 13 , NR 14 C(O)OR 12 , NR 14 C(O)NR I2 R 13 , halo, cyano, trifluoromethyl, SR 12 , S(O)R 12 , SO 2 R 12 , SO 3 R 12 , SO 2 NR I2 R 13 , C(O)SR 12 , CONR 12 R 13 and PO 3 R 12 ;
  • R 12 , R 13 , R 14 are independently selected from the group consisting of hydrogen, C, .3 alkyl, C 2.3 alkanoyl, C 2.3 alkenyl, C 23 alkynyl, and C 3 5 cycloalkyl; or R 12 and R 13 taken together with the nitrogen to which they are attached form a ring having 3 to 7 carbon atoms optionally containing 1, 2, or 3 heteroatoms selected from nitrogen, sulfur, oxygen, or nitrogen, substituted with hydrogen or C l _. alkyl;
  • E is selected from the group consisting of C M alkyl, OR 15 and NR I5 R 16 , with the exception that R 2 is not 3,4-dimethoxyphenyl or 3-methoxyphenyl,
  • F is selected from the group consisting of C ⁇ alkyl, C 2.8 alkenyl, C 3 6 cycloalkyl,
  • OR 12 OC(O)NR 12 R 13 , NR 12 R 13 , NR 14 SO 2 R 12 R 13 , NR 14 C(O)OR 12 , NR 14 C(O)NR 12 R 13 , halo, cyano, trifluoromethyl, SR 12 , S(O)R 12 , SO 2 R 12 , SO 3 R 12 , SO 2 NR 12 R 13 , C(O)SR 12 ,
  • R 15 and R 16 are independently selected from the group consisting of hydrogen, C,_ 3 alkyl, C 2.3 alkanoyl, C 2.3 alkenyl, C 23 alkynyl, and C 3 5 cycloalkyl; or R 15 and R 16 taken together with the nitrogen to which they are attached form a ring having 3 to 7 carbon atoms optionally containing 1, 2, or 3 heteroatoms selected from nitrogen, sulfur, oxygen, or nitrogen, substituted with hydrogen or C,_ 3 alkyl.
  • alkanoyl is used herein at all occurrences to mean a C(0)alkyl group, wherein the alkyl portion is as defined below, including, but not limited to, acetyl, pivaloyl, and the like.
  • alkenyl is used herein at all occurrences to mean a straight or branched chain radical, wherein there is at least one double bond between two of the carbon atoms in the chain, including, but not limited to, ethenyl, 1-propenyl, 2- propenyl, 2-methyl- 1-propenyl, 1-butenyl, 2-butenyI, and the like.
  • alkoxy is used herein at all occurrences to mean a straight or branched chain radical bonded to an oxygen atom, including, but not limited to, methoxy, ethoxy, n- propoxy, isopropoxy, and the like.
  • alkyl refers to a saturated hydrocarbon group joined together by single carbon-carbon bonds.
  • the alkyl hydrocarbon group may be linear, or branched, including, but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, and the like.
  • alkylaryl is used herein at all occurrences to mean a aryl group as defined below attached to an alkyl group as defined above, including, but not limited to, benzyl and phenethyl, and the like.
  • alkylheterocyclyl is used herein at all occurrences to mean a heterocyclic group as defined below attached to an alkyl group as defined above, including, but not limited to, (tetrahydro-3-furanyl)methyl and 3-(4- morpholinyl)propyl, and the like.
  • alkylheteroaryl is used herein at all occurrences to mean a heteroaryl group as defined below attached to an alkyl group as defined above, including, but not limited to, 3-(mranyl)methyl and (2-pyridinyl)propyl, and the like.
  • alkynyl is used herein at all occurrences to mean a straight or branched chain radical, wherein there is at least one triple bond between two of the carbon atoms in the chain, including, but not limited to, acetylene, 1- propylene, 2- propylene, and the like.
  • aryl is used herein at all occurrences to mean 6-14-membered substituted or unsubstituted aromatic ring(s) or ring systems which may include bi- or tri-cyclic systems, including, but not limited to phenyl, naphthalenyl, biphenyl, phenanthryl, anthracenyl, and the like.
  • aryloxy is used herein at all occurrences to mean an aryl group as defined above linked via an oxy group, including, but not limited to, phenoxy, and the like.
  • cycloalkyl is used herein at all occurrences to mean cyclic radicals, which may be mono- or bicyclo- fused ring systems which may additionally include unsaturation, including, but not limited to, cyclopropyl, cyclopentyl, cyclohexyl, 1,2,3,4-tetrahydronaphthalenyl, and the like.
  • halo or halogen are used interchangeably herein at all occurrences to mean radicals derived from the elements chlorine, fluorine, iodine and bromine.
  • heteroaryl is used herein at all occurrences to mean a 5-14- membered substituted or unsubstituted aromatic ring(s) or ring systems which may include bi- or tri-cyclic systems, which ring or ring systems contain 1 to 4 heteroatoms selected from nitrogen, which may be optionally substituted with hydrogen or C galkyl, oxygen, and sulfur, including, but not limited to, indolyl, benzofuranyl, thianaphthenyl, quinolyl, isoquinolyl, pyrrolyl, furanyl, thienyl, pyridyl, and the like.
  • heteroaryloxy is used herein at all occurrences to mean an heteroaryl group as defined above linked via an oxy group, including, but not limited to, 2-pyridinyloxy, and the like.
  • heterocyclic is used herein at all occurrences to mean a saturated or wholly or partially unsaturated 5-10-membered ring system (unless the cyclic ring system is otherwise limited) in which one or more rings contain one or more heteroatoms selected from nitrogen, which may be optionally substituted with hydrogen or C g alkyl, oxygen, and sulfur, including, but not limited to, pyrrolidine, piperidine, piperazine, morpholine, imidazolidine, pyrazolidine, 1,2,3,6- tetrahydropyridine, hexahydroazepine, and the like.
  • Compounds useful in the present invention include: 3-dimethylamino-N-(5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-benzamide; 4-methoxy-N-(5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-benzamide; 1 -ethyl-3-(5-phenyl- lH-pyrrolo[2,3-b]pyridin-3-yl)-urea; benzo[l ,3]dioxole-5-carboxylic acid (5 ⁇ phenyl-lH-pyrrolo[2,3-b] ⁇ yridin-3-yl)- amide;
  • Preferred compounds useful in the present invention include: N-(5-(thiophen-3-yl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide; N-(5-(4-hydroxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
  • More Preferred compounds useful in the present invention include: N-(5-(4-morpholinomethyl-phenyl-l ⁇ -pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide; N-(5-(4-piperidinomethyl-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide; N-(5-(4-pyrrolidinomethyl-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide; N-(5-(4-methylaminomethyl-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide; N-(5-(thiophen-3-yl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide; N-(5-(4-aminophenyl)-lH-pyrrol
  • the compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All of these compounds and diastereomers are contemplated to be within the scope of the present invention.
  • the present compounds can also be formulated as pharmaceutically acceptable salts and complexes thereof.
  • Pharmaceutically acceptable salts are non- toxic salts in the amounts and concentrations at which they are administered.
  • Pharmaceutically acceptable salts include acid addition salts such as those containing sulfate, hydrochloride, fumarate, maleate, phosphate, sulfamate, acetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p- toluenesulfonate, cyclohexylsulfamate and quinate.
  • Pharmaceutically acceptable salts can be obtained from acids such as hydrochloric acid, maleic acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p- toluenesulfonic acid, cyclohexylsulfamic acid, fumaric acid, and quinic acid.
  • acids such as hydrochloric acid, maleic acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p- toluenesulfonic acid, cyclohexylsulfamic acid, fumaric acid, and quinic acid.
  • Pharmaceutically acceptable salts also include basic addition salts such as those containing benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium, ammonium, alkylamine, and zinc, when acidic functional groups, such as carboxylic acid or phenol are present.
  • the boronic acid in the above example may be substituted for various boronic esters, for example pinacolate (4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl) or related boronic esters with no change in the course of the reaction.
  • ⁇ itro compound 3 can then be reduced to the corresponding amine 4 using heterogeneous hydrogenation, for example with palladium on carbon in the presence of 1 atmosphere of hydrogen gas in methanol.
  • the amine 4 can then be acylated with a variety of acylating agents (many commercially available) to provide 5 by several standard methods, for example by treatment with acyl chorides or chloroformates in pyridine at various temperatures or by treatment with isocyanates in pyridine at various temperatures or by treatment with acid anhydrides in pyridine at various temperatures or by treatment with carboxylic acids in the presence of benzotraizol-1- yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP) and triethylamine in N,N-dimethylformamide.
  • acylating agents manufactured commercially available
  • the amine 6 can then be actylated with a variety of acylating agents (many commercially available) to provide 5 by several standard methods, for example by treatment with acyl chorides or chloroformates in pyridine at various temperatures or by treatment with isocyanates in pyridine at various temperatures or by treatment with acid anhydrides in pyridine at various temperatures or by treatment with carboxylic acids in the presence of benzotraizol-1- yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP) and triethylamine in N,N-dimethylformamide.
  • acylating agents manufactured commercially available
  • Amide 7 can then be transformed to 5 by the use of a variety of boronic acids (many commercially available) by standard procedures, for example using tetrakis(triphenylphosphine)palladium as catalyst in N,N-dimethylformamdide / ethanol / aqueous 2M potassium carbonate at 100 °C.
  • the boronic acid in the above example may be substituted for various boronic esters, for example pinacolate (4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl) or related esters with no change in the course of the reaction.
  • R 1 boronic acids or boronic esters are not readily available, then 7 can be converted to 8, for example by bis(pinacolato)diboron, potassium acetate and [1,1 - bis(diphenylphosphino)-ferrocene]palladium(II) chloride in dimethylsulfoxide at 100 °C.
  • Boronate 8 can then be converted to 5 by the use of a variety of aryl or heteroaryl chlorides or bromides or iodides, (many commercially available) by standard procedures, for example using tetrakis(triphenylphosphine)palladium as catalyst in N,N-dimethylformamdide / ethanol / aqueous 2M potassium carbonate at 100 °C.
  • organoboron compounds could be replaced with other organometallic compounds suitable for cross-coupling reactions such as stannanes, silanes, oragnozincs, cuprates, or organomagnesium reagents.
  • Phenylboronic acid (1.10 g, 9.0 mmol, 1.5 equiv)
  • tetrakis(triphenylphosphine)palladium (346 mg, 0.3 mmol, 0.05 equiv)
  • 5-bromo- 3-nitro-lH-pyrrolo[2,3-b]pyridine (1.45 g, 6.0 mmol, 1.0 equiv) were combined in 2/1/1 DMF/EtO ⁇ /aq. 2M K 2 CO 3 (40 mL) and the mixture was heated to reflux for 16 h. The reaction mixture was cooled, poured into ⁇ 2 O and extracted with EtOAc.
  • Butyric anhydride (33 ⁇ l, 0.202 mmol, 1.0 equiv) was added to a solution of the 3-amino-5-phenyl-lH-pyrrolo[2,3-b]pyridine hydrochloride (50 mg, 0.203 mmol, 1.0 equiv) in pyridine (0.5 mL). The reaction mixture was stirred at ambient temperature for 2 h and concentrated. Purification by column chromatography (2% MeO ⁇ in C ⁇ 2 C1 2 ) afforded 20 mg (36%) of the title compound.
  • Example 3 Preparation of (5-phenyl-lH-pyrrolor23-blpyridin-3-yl)-carbamic acid ethyl ester Following the procedure for Example Id, starting with 3-amino-5-phenyl- lH-pyrrolo[2,3-b]pyridine hydrochloride and ethyl chloroformate provided the title compund.
  • Example 14 Preparation of Pyrazine-2-carboxylic acid (5-phenyl-lH-pyrrolor2,3-b1pyridin-3-yl)- amide Following the procedure for Example Id, starting with 3-amino-5-phenyl- lH-pyrrolo[2,3-b]pyridine hydrochloride and pyrazine-2-carbonyl chloride provided the title compund.
  • ESIMS m/z 315.2 (M+).
  • Butyric anhydride (1.16 mL, 7.1 mmol, 1.0 equiv) was added to a solution of 3-amino-5-bromo-lH-pyrrolo[2,3-b]pyridine (1.50 g, 7.1 mmol, 1 equiv) in C ⁇ 2 CL, (10 mL) and pyridine (5 mL). The mixture was stirred at rt for 2 h, then the volatiles were removed and the residue was partitioned between H 2 O and EtOAc. The aqueous layer was extracted with EtOAc, the combined organic layers were washed with brine, dried over MgSO 4 and concentrated to give a solid which was triturated with EtOAc to provide 1.31 g (65%) of the title compound.
  • N-(5-Bromo-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide 28 mg, 0.1 mmol, 1.0 equiv
  • tetrakis(triphenylphosphine)palladium 5.8 mg, 0.005 mmol, 0.05 equiv
  • 3-acetamidobenzeneboronic acid 26.8 mg, 0.15 mmol, 1.5 equiv
  • Example 22 Preparation of N-(5-(3-methyl-phenyl)-lH-pyrroloF2,3-blpyridin-3-yl)-butyr amide Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-butyramide and 3-methylbenzeneboronic acid provided the title compund.
  • N-(5-Bromo-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide 500 mg, 1.8 mmol, 1.0 equiv
  • bis(pinacolato)diboron 450 mg, 1.8 mmol, 1.0 equiv
  • potassium acetate 521 mg, 5.3 mmol, 3.0 equiv
  • Solid PdCl (dppf) 41 mg, 0.05 mmol, 0.03 equiv) was added and the mixture was heated to 100 °C for 16 h. The reaction mixture was then cool, poured into ⁇ 2 O and EtOAc and filtered through Celite.
  • N-(5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH-pyrrolo[3,2- b]pyridin-3-yl)-butyramide (36 mg, 0.1 mmol, 1.0 equiv), tetrakis(triphenylphosphine)palladium (5.8 mg, 0.005 mmol, 0.05 equiv) and 3- bromothiophene (15 ⁇ L, 0.15 mmol, 1.5 equiv) were combined in 2/1/1 DMF/EtO ⁇ /aq. 2M K 2 CO 3 (0.75 mL) and the mixture was heated to 100 °C for 15 h.
  • Example 37 Preparation of N-(5-(3-sulfamoylphenyl)-lH-pyrrolor2,3-b1pyridin-3-yl)-butyramide Following the procedure for Example 34b, starting from N-(5-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH-pyrrolo[3,2-b]pyridin-3-yl)-butyramide and 3-bromobenzenesulfonamide provided the title compund.
  • Example 38 Preparation of N-(5-(4-sulfamoylphenyl)- lH-pyrrolor2,3-blpyridin-3-yl)-butyramide Following the procedure for Example 34b, starting from N-(5-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH-pyrrolo[3,2-b]pyridin-3-yl)-butyr amide and 4-bromobenzenesulfonamide provided the title compund.
  • Example 17b Following the procedure for Example 17b starting from 3-amino-5-bromo ⁇ lH-pyrrolo[2,3-b]pyridine and nicotinoyl chloride hydrochloride provided the title compound.
  • Example 17c Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and 4-dimethylaminobenzeneboronic acid provided the title compund.
  • Example 51 Preparation of 4-methyl-N-(5-phenyl-lH-pyrrolor2,3-b1pyridin-3-yl)-nicotinamide Following the procedure for Example 50, starting from 3-amino-5-phenyl- lH-pyrrolo[2,3-b]pyridine and 4-methylnicotinic acid provided the title compund.
  • Example 52 Preparation of 6-methyl-N-(5-phenyl-lH-pyrrolor2.3-b1pyridin-3-yl)-nicotinamide Following the procedure for Example 50, starting from 3-amino-5-phenyl- lH-pyrrolo[2,3-b]pyridine and 6-methylnicotinic acid provided the title compund.
  • Example 56 Preparation of N-(5-(4-formylphenyl- l ⁇ -pyrrolor23-b1pyridin-3-yl)-butyramide Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-butyramide and 4-formylbenzeneboronic acid provided the title compound.
  • ESIMS m/z 308.2 (M+l).
  • Example 92 Preparation of N-((5-(benzofuran-2-vD- lH-pyrroloF2,3-blpyridin-3-yl)-nicotinamide Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and benzofuran-2-yl-boronic acid provided the title compound.
  • ESIMS m/z 355.3 (M+l).
  • a compound of Formula (I) or a pharmaceutically acceptable salt thereof for the treatment of humans and other mammals, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
  • the present ligands can be administered by different routes including intravenous, intraperitoneal, subcutaneous, intramuscular, oral, topical, transdermal, or transmucosal administration.
  • oral administration is preferred.
  • the compounds can be formulated into conventional oral dosage forms such as capsules, tablets and liquid preparations such as syrups, elixirs and concentrated drops.
  • injection parenteral administration
  • the compounds of the invention are formulated in liquid solutions, preferably, in physiologically compatible buffers or solutions, such as saline solution, Hank's solution, or Ringer's solution.
  • the compounds may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms can also be produced.
  • Systemic administration can also be by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art, and include, for example, for transmucosal administration, bile salts and fusidic acid derivatives.
  • detergents may be used to facilitate permeation.
  • Transmucosal administration for example, may be through nasal sprays, rectal suppositories, or vaginal suppositories.
  • the compounds of the invention can be formulated into ointments, salves, gels, or creams, as is generally known in the art.
  • the amounts of various compounds to be administered can be determined by standard procedures taking into account factors such as the compound IC 50 , EC 50 , the biological half-life of the compound, the age, size and weight of the patient, and the disease or disorder associated with the patient. The importance of these and other factors to be considered are known to those of ordinary skill in the art.
  • Amounts administered also depend on the routes of administration and the degree of oral bioavailability. For example, for compounds with low oral bioavailability, relatively higher doses will have to be administered.
  • the composition is in unit dosage form.
  • a tablet, or capsule may be administered, for nasal application, a metered aerosol dose may be administered, for transdermal application, a topical formulation or patch may be administered and for transmucosal delivery, a buccal patch may be administered.
  • dosing is such that the patient may administer a single dose.
  • Each dosage unit for oral administration contains suitably from 0.01 to 500 mg/Kg, and preferably from 0.1 to 50 mg/Kg, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, calculated as the free base.
  • the daily dosage for parenteral, nasal, oral inhalation, transmucosal or transdermal routes contains suitably from 0.01 mg to 100 mg/Kg, of a compound of Formula(I).
  • a topical formulation contains suitably 0.01 to 5.0% of a compound of Formula (I).
  • the active ingredient may be administered from 1 to 6 times per day, preferably once, sufficient to exhibit the desired activity, as is readily apparent to one skilled in the art.
  • treatment includes, but is not limited to prevention, retardation and prophylaxis of the disease.
  • diseases treatable using the present compounds include, but are not limited to leukemias, solid tumor cancers and metastases, lymphomas, soft tissue cancers, brain cancer, esophageal cancer, stomach cancer, pancreatic cancer, liver cancer, lung cancer, bladder cancer, bone cancer, prostate cancer, ovarian cancer, cervical cancer, uterine cancer, testicular cancer, kidney cancer, head cancer and neck cancer, chronic inflammatory proliferative diseases such as psoriasis and rheumatoid arthritis; proliferative cardiovascular diseases such as restenosis; prolifertive ocular disorders such as diabetic retinopathy; and benign hyperproliferative diseases such as hemangiomas.
  • Composition of Formula (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as syrups, tablets, capsules and lozenges.
  • a syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with a flavoring or coloring agent.
  • a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with a flavoring or coloring agent.
  • any pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include magnesium stearate, terra alba, talc, gelatin, acacia, stearic acid, starch, lactose and sucrose.
  • composition is in the form of a capsule
  • any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatin capsule shell.
  • composition is in the form of a soft gelatin shell capsule
  • any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates or oils, and are incorporated in a soft gelatin capsule shell.
  • Typical parenteral compositions consist of a solution or suspension of a compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a parenterally acceptable oil, for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil or sesame oil.
  • a parenterally acceptable oil for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil or sesame oil.
  • compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or trichlorofluoromefhane.
  • a typical suppository formulation comprises a compound of Formula (I) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent, for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or.their synthetic analogs.
  • a binding and/or lubricating agent for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or.their synthetic analogs.
  • Typical dermal and transdermal formulations comprise a conventional aqueous or non-aqueous vehicle, for example a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.
  • the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer a single dose.
  • Streptavidin coated SPA beads, ATP and 33 P-ATP were obtained from Amersham Pharmacia Biotech, Biotin labeled peptide KVSRSGLYRSPSMPENLNRK(Biotin-xx)NH 2 was obtained from Affiniti Research Products Ltd, assay buffer reagents were obtained from Sigma-Aldrich Co.Ltd. fff84 well assay plates were obtained from Corning Inc.
  • Assay buffer 50 mM HEPES, 50 mM KC1, 5% Glycerol, 1 mM EGTA, 0.001% Tween-20; enzyme/peptide mix: 25 nM Chkl, 2.5 ⁇ M biotin peptide, 7.5 mM 2- mercaptoethanol in assay buffer; ATP mix: 20 ⁇ M ATP at 650kBq/mL, 5mM MgCl 2 in assay buffer.
  • Inhibitors of decreasing concentration, from lOuM were incubated at room temperature for 1 hour together with 5 ⁇ L enzyme/peptide mix and 5 ⁇ L ATP mix. The reaction was stopped with 5 ⁇ L of 0.5M EDTA followed by a further addition of 65uL of 0.2mg/mL SPA beads.
  • a GST-Chkl expression construct was constructed which has the glutathione-S-transferase gene fused to the amino terminus of Chkl kinase via a linker containing a thrombin cleavage site. This construct was cloned into the Baculovirus expression vector, pFASTBAC, and this was used to make the viral stock for the subsequent infection. Spodoptera frugiperda cells (Sf9) were infected with the virus expressing the GST-Chkl and the cells were grown for 3 days, then harvested and frozen down. Purification of GST-Chkl:
  • the GST-Chkl protein was purified as follows: An Sf9 cell pellet expressing GST-Chkl was resuspended on ice in lysis buffer (50mM Tris-Cl, pH 7.5, 250mM NaCl2, ImM dithiothreitol (DTT), 0.1%Brij, 5% (v/v) protease inhibitor cocktail, lmM sodium orthovanadate), cells were lysed by sonication and centrifuged at 100,000xg for 30min The supernatant was added to Glutathione Sepharose 4B, beads, equilibrated in wash buffer (20mM Tris-Cl, pH 7.0, lOmM MgCl2, lOOmM NaCl2, ImM DTT, 0.5%(v/v) protease inhibitor cocktail, ImM sodium orthovanadate).
  • lysis buffer 50mM Tris-Cl, pH 7.5, 250mM NaCl2, ImM dithiothreitol (DTT), 0.1%
  • the mixture was rocked for 30min
  • the resin with the bound GST- Chkl was spun down at 500xg for 5min and washed with 14mls of wash buffer.
  • the beads were spun as above and resuspended in another 14mls of wash buffer.
  • the suspension was transferred into a column and allowed to pack, then the wash buffer was allowed to flow through by gravity.
  • the GST-Chkl was eluted from the column with lOmM Glutathione in 50rnM Tris-Cl, pH 8.0 in 500ul fractions. Protein concentrations were determined on the fractions using Bio-Rad's Protein assay kit as per instructions.
  • Synchronized cells were then returned to complete media containing a DNA-damaging drug such as 50nM topotecan (a dosage we have found to be sufficient to arrest cells in early G2 phase without inducing apoptosis) alone and in combination with test compounds for up to 18 hours.
  • a DNA-damaging drug such as 50nM topotecan (a dosage we have found to be sufficient to arrest cells in early G2 phase without inducing apoptosis) alone and in combination with test compounds for up to 18 hours.
  • Cell cycle profiles were then performed cytometrically using a procedure for propidium iodide staining of nuclei. (Vindelov et al, Cytometry Vol.3, No.5, 1983, 323-327)
  • CHK1 inhibitors would be expected to reverse the G2 arrest caused by the DNA damaging agent. Typical concentration ranges for such activity would be 0.001 to 10 uM.
  • Proliferation studies were performed in a variety of adherent and non- adherent cell lines including Hela S3, HT29, and Jurkat.
  • the proliferation assay utilized a colorimetric change resulting from reduction of the tetrazolium reagent XTT into a formazan product by metabolically active cells
  • CHK1 inhibitors are expected to enhance the cytotoxicity of DNA-damaging chemotherapeutic drugs. Typical concentration ranges for such activity would be 0.001 to 10 uM. Other assays for cellular proliferation or cytotoxicity could also be used with test compounds, and these assays are known to those skilled in the art.
  • Formulations for pharmaceutical use incorporating compounds of the present invention can be prepared in various forms and with numerous excipients. Examples of such formulations are given below:

Abstract

Novel compounds useful in the inhibition of damage response kinases are provided.

Description

CHK1 KINASE INHIBITORS
FIELD OF THE INVENTION
The present invention relates to damage response kinase inhibitors, especially checkpoint kinase ("chkl kinase") inhibitors, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat various forms of cancer and hyperproliferative disorders. BACKGROUND OF THE INVENTION
The cellular response to DNA damage involves cell cycle delays, increased repair and apoptosis (Zhou and Elledge Nature 2000. 408:433-439). Although many effective cancer therapies work by causing DNA damage induced apoptosis, resistance to these agents remains a significant limitation in the treatment of cancer. One important mechanism of drug resistance is attributed to cell cycle delays (also called checkpoints) and repair activation, which provides both the opportunity and capacity for cells to repair DNA damage. It is likely that approaches abrogating these survival DNA damage responses would have significant clinical utility.
Among different DNA damage response kinases, Chkl was linked to survival responses including checkpoints. Mice lacking CHK1 die in early embryogenesis (Liu et al.Gerce & Dev. 2000 14: 1448-1459; Takai et al, Gene & Dev. 2000. 14: 1439-1447). ES cells expressing a conditional CHK1 gene die of p53-independent apoptosis after loss of CHK Prior to their death, these cells become incapable of preventing mitotic entry in response to IR (Liu et al.Gene & Dev. 2000 14: 1448-1459), demonstrating that Chkl is required for the G2 DNA damage checkpoint in mammals as previously observed in other organisms.
Chkl prevents mitotic entry as follows. Arrest in G2 is regulated by the maintenance of inhibitory phosphorylation of Cdc2 (Nurse Cell 1997. 91: 865-867). Cdc2 dephosphorylation and activation is catalyzed by the dual specificity phosphatase Cdc25 (Morgan Nature 1995. 374: 131-134). Recent evidence indicates that part of the G2/M DΝA checkpoint mechanism involves inactivation and translocation of Cdc25C into the cytoplasm. This is at least partially mediated by phosphorylation on Ser-216 in Cdc25C and its consequent binding with 14-3-3 proteins (Peng et al., Science 1997. 277: 1501-1505; Dalai et al. Mol. Cell Bio. 1999. 19: 4465-4479; Yang et al EMBO J. 1999. 18: 2174-2183). Chkl (Sanchez et al. Science 1997. 277: 1497-1501) has been shown to phosphorylate Cdc25C at Ser- 216 in vitro. This modification is thought to maintain Cdc25C phosphorylation in cells arrested at G2/M in response to DNA damage. Recently, staurosporine-like kinase inhibitors, UCN-01 and SB-218078, have been shown to be potent Chkl inhibitors (Jackson et al. Cancer Res. 2000. 60: 566-572; Graves et al. J. Biol. Chem. 2000. 275: 5600-5605). In vivo, they can abrogate the G2/M checkpoint induced by DNA damaging agents and enhance the cytotoxicities of the DNA damaging agents. Thus it is likely that a specific Chkl inhibitor could be used clinically in combination treatment with coventional therapies. Since Chkl is an essential kinase for regular cell cycle (Liu et al.Gene & Dev. 2000 14: 1448-1459), it is possible that Chkl inhibitor could also be used alone in cancer therapy.
Based on the foregoing, there is a need to identify a potent chkl kinase inhibitors for the treatment of the various aforementioned indications.
SUMMARY OF THE INVENTION
The present invention involves pyrolo[2,3-b]pyridine compounds represented by Formula (I) hereinbelow, pharmaceutical compositions comprising such compounds and methods of inhibiting kinase as well as specific assays to detect inhibition of chkl kinase activity.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides compounds of Formula (I), hereinbelow:
Figure imgf000003_0001
(I) wherein:
R1 is aryl or heteroaryl, wherein aryl or heteroaryl may optionally be substituted by one or more of group A and on any position with the exception that R1 is not 3,4- dichlorophenyl, with the preferred substitution being 3-,4- or 5-alkoxy- or hydroxy- or amino- or hydroxymethyl- or aminomethyl- or acetamido- or aminosulfamoyl- or dimethylamino- phenyl including di- and tri-substitution or 3-thienyl, with the more preferred substitution being 4-hydroxy-3-methoxyphenyl or 3-acetamidophenyl or 3,4-dimethoxyphenyl or 4-aminophenyl or 4-aminomethylphenyl or 4- dimethylaminomethylpheny 1 ;
A is selected from the group consisting of C,.I0 alkyl, C,.,0 alkanoyl, C2.10 alkenyl, C2.]0 alkynyl, C3 10 cycloalkyl, C0_6 alkylaryl, C0.6 alkylheterocyclyl, CM alkylheteroaryl, C(=NH)R3, COR3, CONR3R4, CON(O)R3R4, CO2R3, C(O)SR3, C(S)R3, cyano, trifluoromethyl, NR3R4, N(O)R3R4, NR3COR4, NR3CONR4R5, NR3CON(O)R R5, NR3CO2R3, NR3C(O)SR3, NR3SO2R3, nitro, OR3, OCF3, aryloxy, heteroaryloxy, SR3, S(O)R3, S(O)2R3, SCF3, S(O)CF3, S(0)2CF3, SO2NR3R4, SO3R3, PO3R3R4, and halo, wherein CM0 alkyl, C,.10 alkanoyl, C2.10 alkenyl, C2.10 alkynyl, C3.10 cycloalkyl, C0.5 alkylaryl, C0.5 alkylheterocyclyl, C05 alkylheteroaryl, (CH2)0.5heteroaryl, aryloxy, and heteroaryloxy may be optionally substituted by one or more of group B and on any position;
B is selected from the group consisting of C,.10 alkyl, C,.10 alkanoyl, C2.10 alkenyl, C2 10 alkynyl, C3 ]0 cycloalkyl, C0_5 alkylaryl, C0.5 alkylheterocyclyl, C0 6 alkylheteroaryl, C(=NH)R3, COR3, CONR3R4, CON(O)R3R4, CO2R3, C(O)SR3, C(S)R3, cyano, trifluoromethyl, NR3R4, N(O)R3R4, NR3COR4, NR3CONR4R5, NR3CON(O)R4R5, NR3CO2R3, NR3C(O)SR3, NR3SO2R3, nitro, OR3, OCF3, aryloxy, heteroaryloxy, SR3, S(O)R3, S(O)2R3, SCF3, S(O)CF3, S(O)2CF3, SO2NR3R4, SO3R3, PO3R3R4, and halo, wherein CM0 alkyl, C[.10 alkanoyl, C2.10 alkenyl, C2.10 alkynyl, C3.10 cycloalkyl, C0.6 alkylaryl, CM alkylheterocyclyl, C06 alkylheteroaryl, (CH2)06heteroaryl, aryloxy, and heteroaryloxy may be optionally substituted by one or more of group C and on any position;
R3, R4, and R5 are independently selected from the group consisting of hydrogen, C,_10 alkyl, C,.10 alkanoyl, C2.I0 alkenyl, C2.10 alkynyl, C3.10 cycloalkyl, CM alkylaryl, CM alkylheterocyclyl, and C0.6 alkylheteroaryl; or R3 and R4 taken together with the nitrogen to which they are attached form a ring having 3 to 7 carbon atoms optionally containing 1, 2, or 3 heteroatoms selected from nitrogen, sulfur, oxygen, or nitrogen, substituted with hydrogen, C,.6 alkyl or (CH2)0.3aryl, wherein any of the foregoing may be optionally substituted by one or more of group C and on any position;
C is selected from the group consisting of C,.10 alkyl, C 0 alkanoyl, C2.10 alkenyl, C2.10 alkynyl, C3_i0 cycloalkyl, CM alkylaryl, C0.6 alkylheterocyclyl, C0_6 alkylheteroaryl, C(=NH)R6, COR6, CONR6R7, CON(O)R6R7, CO2R6, C(O)SR6, C(S)R6, cyano, trifluoromethyl, NR6R7, N(O)R6R7, NR6COR6, NR6CONR7R8, NR6CON(O)R7Rs, NR6CO2R6, NR6C(O)SR<i, NR6SO2R6, nitro, OR6, OCF3, aryloxy, heteroaryloxy, SR6, S(O)R6, S(O)2R6, SCF3, S(O)CF3, S(O)2CF3, SO2NR6R7, SO3R6, PO3R6R7, and halo, wherein C1 8 alkyl, Cj_8 alkanoyl, C2 8 alkenyl, C2.8 alkynyl, C3.8 cycloalkyl, C0 6 alkylaryl, C0.6 alkylheterocyclyl, C0_6 alkylheteroaryl may be optionally substituted by one or more of C(=NH)R6, COR6, CONR6R7, CON(O)R6R7, CO2R6, C(O)SR6, C(S)R6, cyano, trifluoromethyl, NR6R7, N(O)R6R7, NR6COR6, NR6CONR7R8, NR6CON(O)R7R8, NR6CONR6R7R8Y, NR6CO2R6, NR6C(O)SR6, NR6SO2R6, nitro, OR6, aryloxy, heteroaryloxy, SR6, S(O)R6, S(O)2R6, SO2NR6R7, SO3R6, PO3R6R7, or halo, and on any position;
R6, R7, and R8 are independently selected from the group consisting of hydrogen, C,.,,, alkyl, C,.]0 alkanoyl, C2.10 alkenyl, C2.10 alkynyl, C3.10 cycloalkyl, C0.6 alkylaryl, C0.6 alkylheterocyclyl, and C0.6 alkylheteroaryl; or R7 and R8 taken together with the nitrogen to which they are attached form a ring having 3 to 7 carbon atoms optionally containing 1, 2, or 3 heteroatoms selected from nitrogen, sulfur, oxygen, or nitrogen, substituted with hydrogen, C alkyl or (CH2)0.3aryl; R" is selected from the group consisting of Cι_8 alkyl, C2.8 alkenyl, C3.6 cycloalkyl, OR9, NR10Rπ, phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazolinyl, thiazinyl, pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl and thiadiazolyl, wherein alkyl and alkenyl and cycloalkyl may optionally be substituted with one of more of group D and at any position and wherein phenyl may be optionally subtituted at positions 3-, 4-, and 5- with one to three of group E and wherein pyridyl, pyridazinyl, pyrimidinyl, pyrazolinyl, thiazinyl, pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl and thiadiazolyl may optionally be substituted by one or more of group F and at any position, with the preferred substitution being n- propyl or pyridyl or pyrazolinyl, with the more preferred substitution being 3- pyridyl.
R9 is hydrogen or .6 alkyl, wherein any of the foregoing groups are optionally substituted with one or more of group D and at any position, with the exception that
R9 is not tert-butyl;
R10 is selected from the group consisting of hydrogen, methyl and ethyl;
Ru is selected from the group consisting of hydrogen, Cj„6 alkyl, C2.8 alkenyl and C3_6 cycloalkyl, wherein any of the foregoing groups are optionally substituted with one or more of group D and at any position;
R10 and Ru taken together with the nitrogen to which they are attached may form a ring having 3 to 7 carbon atoms optionally containing 1, 2, or 3 heteroatoms selected from nitrogen, sulfur, oxygen, or nitrogen, substituted with hydrogen or C,_6 alkyl;
D is selected from the group consisting of C 6 alkyl, C2.8 alkenyl, C3.6 cycloalkyl,
OR12, OC(O)NR12R13, NR14SO2R12R13, NR14C(O)OR12, NR14C(O)NRI2R13, halo, cyano, trifluoromethyl, SR12, S(O)R12, SO2R12, SO3R12, SO2NRI2R13, C(O)SR12, CONR12R13 and PO3R12;
R12, R13, R14 are independently selected from the group consisting of hydrogen, C,.3 alkyl, C2.3 alkanoyl, C2.3 alkenyl, C23 alkynyl, and C3 5 cycloalkyl; or R12 and R13 taken together with the nitrogen to which they are attached form a ring having 3 to 7 carbon atoms optionally containing 1, 2, or 3 heteroatoms selected from nitrogen, sulfur, oxygen, or nitrogen, substituted with hydrogen or Cl _. alkyl;
E is selected from the group consisting of CM alkyl, OR15 and NRI5R16, with the exception that R2 is not 3,4-dimethoxyphenyl or 3-methoxyphenyl,
F is selected from the group consisting of C^ alkyl, C2.8 alkenyl, C3 6 cycloalkyl,
OR12, OC(O)NR12R13, NR12R13, NR14SO2R12R13, NR14C(O)OR12, NR14C(O)NR12R13, halo, cyano, trifluoromethyl, SR12, S(O)R12, SO2R12, SO3R12, SO2NR12R13, C(O)SR12,
CONR12R13 and PO3R12;
R15 and R16 are independently selected from the group consisting of hydrogen, C,_3 alkyl, C2.3 alkanoyl, C2.3 alkenyl, C23 alkynyl, and C3 5 cycloalkyl; or R15 and R16 taken together with the nitrogen to which they are attached form a ring having 3 to 7 carbon atoms optionally containing 1, 2, or 3 heteroatoms selected from nitrogen, sulfur, oxygen, or nitrogen, substituted with hydrogen or C,_3 alkyl.
As used herein, the term "alkanoyl " is used herein at all occurrences to mean a C(0)alkyl group, wherein the alkyl portion is as defined below, including, but not limited to, acetyl, pivaloyl, and the like.
The term "alkenyl" is used herein at all occurrences to mean a straight or branched chain radical, wherein there is at least one double bond between two of the carbon atoms in the chain, including, but not limited to, ethenyl, 1-propenyl, 2- propenyl, 2-methyl- 1-propenyl, 1-butenyl, 2-butenyI, and the like.
The term "alkoxy" is used herein at all occurrences to mean a straight or branched chain radical bonded to an oxygen atom, including, but not limited to, methoxy, ethoxy, n- propoxy, isopropoxy, and the like.
The term "alkyl" refers to a saturated hydrocarbon group joined together by single carbon-carbon bonds. The alkyl hydrocarbon group may be linear, or branched, including, but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, and the like.
The term "alkylaryl" is used herein at all occurrences to mean a aryl group as defined below attached to an alkyl group as defined above, including, but not limited to, benzyl and phenethyl, and the like.
The term "alkylheterocyclyl" is used herein at all occurrences to mean a heterocyclic group as defined below attached to an alkyl group as defined above, including, but not limited to, (tetrahydro-3-furanyl)methyl and 3-(4- morpholinyl)propyl, and the like.
The term "alkylheteroaryl" is used herein at all occurrences to mean a heteroaryl group as defined below attached to an alkyl group as defined above, including, but not limited to, 3-(mranyl)methyl and (2-pyridinyl)propyl, and the like.
The term "alkynyl" is used herein at all occurrences to mean a straight or branched chain radical, wherein there is at least one triple bond between two of the carbon atoms in the chain, including, but not limited to, acetylene, 1- propylene, 2- propylene, and the like. The term "aryl" is used herein at all occurrences to mean 6-14-membered substituted or unsubstituted aromatic ring(s) or ring systems which may include bi- or tri-cyclic systems, including, but not limited to phenyl, naphthalenyl, biphenyl, phenanthryl, anthracenyl, and the like.
The term "aryloxy" is used herein at all occurrences to mean an aryl group as defined above linked via an oxy group, including, but not limited to, phenoxy, and the like.
The terms "cycloalkyl" is used herein at all occurrences to mean cyclic radicals, which may be mono- or bicyclo- fused ring systems which may additionally include unsaturation, including, but not limited to, cyclopropyl, cyclopentyl, cyclohexyl, 1,2,3,4-tetrahydronaphthalenyl, and the like.
The terms "halo" or "halogen" are used interchangeably herein at all occurrences to mean radicals derived from the elements chlorine, fluorine, iodine and bromine.
The term "heteroaryl" is used herein at all occurrences to mean a 5-14- membered substituted or unsubstituted aromatic ring(s) or ring systems which may include bi- or tri-cyclic systems, which ring or ring systems contain 1 to 4 heteroatoms selected from nitrogen, which may be optionally substituted with hydrogen or C galkyl, oxygen, and sulfur, including, but not limited to, indolyl, benzofuranyl, thianaphthenyl, quinolyl, isoquinolyl, pyrrolyl, furanyl, thienyl, pyridyl, and the like.
The term "heteroaryloxy" is used herein at all occurrences to mean an heteroaryl group as defined above linked via an oxy group, including, but not limited to, 2-pyridinyloxy, and the like.
The term "heterocyclic" is used herein at all occurrences to mean a saturated or wholly or partially unsaturated 5-10-membered ring system (unless the cyclic ring system is otherwise limited) in which one or more rings contain one or more heteroatoms selected from nitrogen, which may be optionally substituted with hydrogen or C g alkyl, oxygen, and sulfur, including, but not limited to, pyrrolidine, piperidine, piperazine, morpholine, imidazolidine, pyrazolidine, 1,2,3,6- tetrahydropyridine, hexahydroazepine, and the like. Compounds useful in the present invention include: 3-dimethylamino-N-(5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-benzamide; 4-methoxy-N-(5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-benzamide; 1 -ethyl-3-(5-phenyl- lH-pyrrolo[2,3-b]pyridin-3-yl)-urea; benzo[l ,3]dioxole-5-carboxylic acid (5~phenyl-lH-pyrrolo[2,3-b]ρyridin-3-yl)- amide;
N-(5-(3-carboxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide; N-(5-(4-chloro-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide; N-(5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-benzamide; N-(5-(4-carboxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide; 4-acetylamino-N-(5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-benzamide; N-(5-(3-chIoro-phenyl)-pyrrolo[2,3-b]pyridin-3-yl)-butyr amide; N-(5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-isonicotinamide; acetic acid (5-phenyl-lH-pyrτolo[2,3-b]pyridin-3-ylcarbamoyl)-methyl ester; 6-(2-(pyrrolidin-l-yl)ethyl-N-(5-phenyl-lΗ-pyrrolo[2,3-b]pyridin-3-yl)- nicotinamide;
3-hydroxy-N-(5-phenyl-lH~pyrrolo[2,3-b]pyridin-3-yl)-benzamide; N-(5-(4-cyano-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide; N-(5-(4-acetyl-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide; N-(5-(pyridin-3-yl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide; N-(5-(3-fiuoro-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide; N-(5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide; N-(5-(3-methyl-phenyI)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide; (5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-carbamic acid ethyl ester; N-(5-(4-methylsulfonyl-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide; 2-methoxy-N-(5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-acetamide; (lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(3-hydroxymethyl-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide; pyridine-2-carboxylic acid (5-phenyl- lH-pyrrolo[2,3-b]pyridin-3-yl)-amide; N-(5-(pyridin-4-yl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide; N-(5-phenyl-lH-pyrrolo[2,3-b]ρyridin-3-yl)-isobutyramide; N-(5-(4-dimethylamino-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-(4-hydroxymethyl-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
6-methyl-N-(5-phenyl-lΗ-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide; thiophene-2-carboxylic acid (5-phenyl- lH-pyrrolo[2,3-b]pyridin-3-yl)-amide;
N-(5-(4-sulfamoylphenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-(3-aminophenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyr amide;
N-(5-(4-acetamido-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(4-hydroxy -phenyl)- lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(3-methoxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide; furan-2-carboxylic acid (5-(4-hydroxy-phenyl)- lH-pyrrolo[2,3-b]pyridin-3-yl)- amide; furan-3 -carboxylic acid (5-(4-hydroxy-phenyl)- lH-pyrrolo[2,3-b]pyridin-3-yl)- amide; thiophene-3-carboxylic acid (5-(4-hydroxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)- amide; pyrrole-2-carboxylic acid (5-(4-hydroxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)- amide
N-(5-(4-methyl-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-(4-(mo holin-l-yl)-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-(4-(4-methyl-piperazin-l-yl)-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)- butyr amide;
5-methyl-N-(5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
5-bromo-N-(5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
2,6-dimethoxy-N-(5-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(4-aminomethylphenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(4-aminomethylphenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(3-formylphenyl-lΗ-pyrrolo[2,3-b]pyridin-3-yl)-butyr amide;
N-(5-(4-formylphenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyr amide;
N-(5-(3-formylphenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(4-formylphenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide; N-(5-(4-(4-t-butoxycarbonyl)-piperazinomethyl-phenyl-lH-pyrrolo[2,3-b]pyridin-3- yl)-nicotinamide;
N-(5-(4-(4-t-butoxycarbonyl)-piperazinomethyl-phenyl-lH-pyrrolo[2,3-b]pyridin-3- yl)-nicotinamide;
N-(5-(3-(4-t-butoxycarbonyl)-methyl-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)- nicotinamide;
N-(5-(3 -morpholinomethyl-phenyl- 1 H-pyrrolo [2 ,3 -b]pyridin-3 -yl)-butyramide ;
N-(5-(3-(4-methylpiperazinomethyl)-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)- butyr amide;
N-(5-(4-morpholinomethyl-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-(4-(4-methylpiperazinomethyl)-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)- butyr amide;
2-methyl-N-((5-(4-hydroxy-3-methoxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)- benzamide;
2-chloro-N-((5-(4-hydroxy-3-methoxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)- benzamide;
N-((5-(4-hydroxy-3-methoxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-2- methoxybenza ide ;
2-hydroxy-N-((5-(4-hydroxy-3-methoxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)- benzamide; pyrimidine-5-carboxylic acid-((5-(4-hydroxy-3-methoxy-phenyl)-lH-ρyrrolo[2,3- b]pyridin-3-yl)-amide;
N-((5-(benzothiophen-3-yl)-lH-ρyrrolo[2,3-b]pyridin-3-y])-nicotinamide;
N-((5-(thiophen-2-yl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-((5-(3-biphenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-((5-(benzofuran-2-yl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-((5-(indol-5-yl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide; and pyrazine-2-carboxylic acid ((5-(4-hydroxy-3-methoxy-phenyl)- lH-pyrrolo[2,3- b]ρyridin-3-yl)-amide;
Preferred compounds useful in the present invention include: N-(5-(thiophen-3-yl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide; N-(5-(4-hydroxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-(3,4-dimethoxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-(3-sulfamoylphenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-(3-acetamide-phenyl)-lH-pyrrolo[2,3-b]ρyridin-3-yl)-butyramide;
N-(5-(naphthalen-2-yl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
4-methyl-N-(5-phenyl-lΗ-pyrrolo[2,3-b]ρyridin-3-yl)-nicotinamide; pyrazine-2-carboxylic acid (5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-arnide;
N-(5-(4-aminomethylphenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-ρhenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(4-methoxyphenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(4-dimethylamino-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(3,4-(methylenedioxy)-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(4-diethanolarm^omethyl-phenyl-lΗ-pyιτolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5 -(3 -dimethylaminomethyl-phenyl- 1 H-pyrrolo [2 ,3 -b]pyridin-3 -yl)-nicotinamide;
N-(5-(3-(4-methylpiperazinomethyl)-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)- nicotinamide;
N-(5-(3-morpholinomethyl-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(3-diethanolaminomethyl-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(3,5-dimethyl-4-hydroxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)- nicotinamide;
N-(5-(4-hydroxymethyl-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
More Preferred compounds useful in the present invention include: N-(5-(4-morpholinomethyl-phenyl-lΗ-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide; N-(5-(4-piperidinomethyl-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide; N-(5-(4-pyrrolidinomethyl-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide; N-(5-(4-methylaminomethyl-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide; N-(5-(thiophen-3-yl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide; N-(5-(4-aminophenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide; N-(5 -(3 ,4-dimethoxy-phenyl)- lH-pyrrolo [2 , 3 -b]pyridin-3 -yl)-nicotinamide ; N-(5-(3-acetarm^o-phenyl)-lH-pyιτolo[2,3-b]pyridin-3-yl)-nicotinamide; N-(5-(4-hydroxy-3-methoxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide; N-(5-(4-(dimethylaminomethyl)-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)- nicotinamide;
N-(5-(4-(morpholin-l-yl)-phenyl)-lH-pynOlo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(4-(4-methyl-piperazin-l-yl)-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)- nicotinamide.
Other compounds useful in the present invention include:
Figure imgf000013_0001
and
Figure imgf000013_0002
The compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All of these compounds and diastereomers are contemplated to be within the scope of the present invention.
The present compounds can also be formulated as pharmaceutically acceptable salts and complexes thereof. Pharmaceutically acceptable salts are non- toxic salts in the amounts and concentrations at which they are administered.
Pharmaceutically acceptable salts include acid addition salts such as those containing sulfate, hydrochloride, fumarate, maleate, phosphate, sulfamate, acetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p- toluenesulfonate, cyclohexylsulfamate and quinate. Pharmaceutically acceptable salts can be obtained from acids such as hydrochloric acid, maleic acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p- toluenesulfonic acid, cyclohexylsulfamic acid, fumaric acid, and quinic acid.
Pharmaceutically acceptable salts also include basic addition salts such as those containing benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium, ammonium, alkylamine, and zinc, when acidic functional groups, such as carboxylic acid or phenol are present.
Compounds such as formula (I) can be prepared by general methods from known or commercially available starting materials. Several methods for the preparation of compounds of formula (I) are shown below.
Compounds of formula (I) wherein R1 is not sensitive to mild hydrogenation conditions can be prepared according to Scheme I. 5-Bromo-lH-pyrrolo[2,3- b]pyridine (1) (Mazeas,Heterocy/cei' 1999. 50: 1-65-1080.) can be nitrated by several methods, for example with fuming nitric acid, or mixtures of nitric and sulfuric acids to provide compound 2. Bromide 2 can then be transformed into 3 by the use of a variety of boronic acids (many commercially available) by standard procedures, for example using tetrakis(triphenylphosphine)palladium as catalyst in
N,N-dimethylformamide / ethanol / aqueous 2M potassium carbonate at 100 °C.
Alternatively, the boronic acid in the above example may be substituted for various boronic esters, for example pinacolate (4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl) or related boronic esters with no change in the course of the reaction. Νitro compound 3 can then be reduced to the corresponding amine 4 using heterogeneous hydrogenation, for example with palladium on carbon in the presence of 1 atmosphere of hydrogen gas in methanol. The amine 4 can then be acylated with a variety of acylating agents (many commercially available) to provide 5 by several standard methods, for example by treatment with acyl chorides or chloroformates in pyridine at various temperatures or by treatment with isocyanates in pyridine at various temperatures or by treatment with acid anhydrides in pyridine at various temperatures or by treatment with carboxylic acids in the presence of benzotraizol-1- yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP) and triethylamine in N,N-dimethylformamide.
Scheme I
Figure imgf000015_0001
(a) fuming nitric acid, 0 °C. (b) R'B(OH)2, (PPh3)4Pd, DMF/EtOH/aq. 2M K^COj, 100 °C. (c) H2, Pd/C, MeOH, rt. (d) R2COCl, pyr, rt; or R2CNO, pyr, rt; or (R2CO)2O, pyr, rt; or R2CO2H, BOP, Et3N, DMF, rt.
Compounds of formula (I) wherein R1 is sensitive to mild hydrogenation conditions or wherein R'B(OH)2 or related reagents are unavailable, can be prepared according to Scheme II. 5-Bromo-3-nitro-lH-pyrrolo[2,3-b]pyridine (2) can be reduced to amine 6, for example by stannous chloride in glacial acetic acid and 12M hydrochloride acid at 80 °C. The amine 6 can then be actylated with a variety of acylating agents (many commercially available) to provide 5 by several standard methods, for example by treatment with acyl chorides or chloroformates in pyridine at various temperatures or by treatment with isocyanates in pyridine at various temperatures or by treatment with acid anhydrides in pyridine at various temperatures or by treatment with carboxylic acids in the presence of benzotraizol-1- yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP) and triethylamine in N,N-dimethylformamide. Amide 7 can then be transformed to 5 by the use of a variety of boronic acids (many commercially available) by standard procedures, for example using tetrakis(triphenylphosphine)palladium as catalyst in N,N-dimethylformamdide / ethanol / aqueous 2M potassium carbonate at 100 °C. Alternatively, the boronic acid in the above example may be substituted for various boronic esters, for example pinacolate (4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl) or related esters with no change in the course of the reaction. If the desired R1 boronic acids or boronic esters are not readily available, then 7 can be converted to 8, for example by bis(pinacolato)diboron, potassium acetate and [1,1 - bis(diphenylphosphino)-ferrocene]palladium(II) chloride in dimethylsulfoxide at 100 °C. Boronate 8 can then be converted to 5 by the use of a variety of aryl or heteroaryl chlorides or bromides or iodides, (many commercially available) by standard procedures, for example using tetrakis(triphenylphosphine)palladium as catalyst in N,N-dimethylformamdide / ethanol / aqueous 2M potassium carbonate at 100 °C.
Scheme II
Figure imgf000016_0001
8 5
(a) SnCl2, HOAc, 12M HC1, 80 °C. (b) R2COCl, pyr, rt; or R2CNO, pyr, rt; or (R2CO)2O, pyr, rt; or R2CO2H, BOP, Et3N, DMF, rt. (c) R1B(OH)2, (PPh3)4Pd, DMF/EtOH/aq. 2M K2CO3, 100 °C. (d) bis(pinacolato)diboron, Pd(dppf Cl2, KOAc, DMSO, 100 °C. (e) RJBr, (PPh3) Pd, DMF/EtOH/aq. 2M K2CO3, 100 °C. Alternatively to the routes above, the organoboron compounds could be replaced with other organometallic compounds suitable for cross-coupling reactions such as stannanes, silanes, oragnozincs, cuprates, or organomagnesium reagents.
While not intended to be limiting in any way, the following examples illustrate the embodiments of the present invention.
Example 1 Preparation of N-(5-phenyl- lH-pyrrolor2,3-b1pyridin-3-yl)-benzamide
a) 5-Bromo-3-nitro- lH-pyrrolo[2,3-b]pyridine
5-Bromo-l-H-pyrrolo[2,3-b]pyridine (4.4 g, 22.3 mmol) was added in portions to fuming nitric acid (25 mL) at 0 °C over 15 min. The solution was allowed to stir at 0 °C for 1 h, then was poured into ice water. The resulting solid was filtered and dried to provide 4.5 g (83%) of the title compound. Η ΝMR (400 MHz, CD3S(O)CD3) δ 8.90 (s, IH), 8.56-8.54 (m, 2H); ESIMS m/z = 242.0, 244.0 (M+l).
b) 3-Νitro-5-phenyl-lH-pyrrolo[2,3-b]pyridine
Phenylboronic acid (1.10 g, 9.0 mmol, 1.5 equiv), tetrakis(triphenylphosphine)palladium (346 mg, 0.3 mmol, 0.05 equiv) and 5-bromo- 3-nitro-lH-pyrrolo[2,3-b]pyridine (1.45 g, 6.0 mmol, 1.0 equiv) were combined in 2/1/1 DMF/EtOΗ/aq. 2M K2CO3 (40 mL) and the mixture was heated to reflux for 16 h. The reaction mixture was cooled, poured into Η2O and extracted with EtOAc. The organic extracts were combined, washed with brine, dried over MgSO4, filtered and the filtrate was concentrated. The residue was purified by column chromatography (SiO , 2/1 EtOAc/hexanes to EtOAc) to give a solid which triturated with acetone to provide 1.03 g (72%) of the title compound. 1H NMR (400 MHz, CD3S(O)CD3) δ 8.89 (s, IH), 8.76 (d, J = 2.2, IH), 8.59 (d, J = 2.3, IH), 7.77 (d, J = 1.2, 2H), 7.54 (t, J= 7.3, 2H), 7.45 (t, J= 7.4, IH); ESIMS m/z = 240.0 (M+l). c) 3-Amino-5-phenyl-lH-pyrrolo[2,3-b]pyridine
3-Nitro-5-ρhenyl-lH-pyrrolo[2,3-b]pyridine (250 mg, 1.05 mmol) and 5% Pd/C (100 mg) were hydrogenated at 1 atm in MeOΗ (30 mL) overnight. The mixture was filtered through Celite and the filtrate was concentrated. The residue was partitioned between 1M NaOΗ and CΗ2C12 and extracted with CH2C12. The combined organic extracts were dried (NajSO and concentrated to give 202 mg (92%) of the title compound. Η NMR (400 MHz, CD3S(O)CD3) δ 10.69 (s, IH), 8.42 (d, / = 2.1, IH), 8.22 (d, / = 1.9, IH), 7.68 (d, /= 7.1, 2H), 7.48 (t, / = 7.5, 2H), 7.34 (t, J= 7.3, IH), 6.69 (d, /= 2.1, IH), 4.47 (brs, 2H).
d) N-(5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-benzamide
3-Amino-5-phenyl-lH-pyrrolo[2,3-b]pyridine hydrochloride (25 mg, 0.1 mmol, 1.0 equiv) was dissolved in pyridine (0.3 mL), benzoyl chloride (15 mL, 0.12 mmol, 1.2 equiv) was added and the mixture was heated to 80 °C for 18 h. The reaction mixture was cooled, concentrated and the resiude purified by reverse-phase ΗPLC to give 5 mg (16%) of the title compound. 1H ΝMR (400 MHz, CD3OD) δ 8.95 (s, IH), 8.62 (brs, IH), 8.07-8.00 (m, 3H), 7.74 (dd, 7= 9.4, 1.4, 2H), 7.63-7.47 (m, 5H), 7.43 (tt, J = 4.4, 1.1, IH); ESIMS m/z = 314.4 (M+l).
Example 2 Preparation of N-(5-phenyl- lH-pyrrolor2 -b1pyridin-3-yl)-butyramide
Butyric anhydride (33 μl, 0.202 mmol, 1.0 equiv) was added to a solution of the 3-amino-5-phenyl-lH-pyrrolo[2,3-b]pyridine hydrochloride (50 mg, 0.203 mmol, 1.0 equiv) in pyridine (0.5 mL). The reaction mixture was stirred at ambient temperature for 2 h and concentrated. Purification by column chromatography (2% MeOΗ in CΗ2C12) afforded 20 mg (36%) of the title compound. 1H ΝMR (CD3S(O)CD3) δ 11.6 (s, IH), 10.2 (s, IH), 8.76 (d, IH), 8.05 (d, IH), 7.94 (d, 2H), 7.74 (t, 2H), 7.61 (t, IH), 2.60 (t, 2H), 1.89 (m, 2H), 1.18 (t, 3H); APC S m/z = 280 (M+l).
Example 3 Preparation of (5-phenyl-lH-pyrrolor23-blpyridin-3-yl)-carbamic acid ethyl ester Following the procedure for Example Id, starting with 3-amino-5-phenyl- lH-pyrrolo[2,3-b]pyridine hydrochloride and ethyl chloroformate provided the title compund. 1H NMR (400 MHz, CD3OD) δ 8.58 (s, IH), 8.52 (s, IH), 1.10-1.63 (m, 3H), 7.50 (t, J = 7.4, 2H), 7.40 (t, / = 7.1, IH), 4.23 (q, J = 7.1, 2H), 1.33 (t, J= 6.9, 3H); ESIMS m/z = 282.0 (M+l).
Example 4 Preparation of l-ethyl-3-(5-phenyl-lH-pyrrolor2,3-b1pyridin-3-yl)-urea
Following the procedure for Example Id, starting with 3-amino-5-phenyl- lH-pyrrolo[2,3-b]pyridine hydrochloride and ethyl isocyanate provided the title compund. 1H NMR (400 MHz, CD3S(O)CD3) δ 8.66 (d, J = 1.6, IH), 8.57 (s, IH), 7.73-7.70 (m, 2H), 7.66 (s, IH), 7.52 (t, J = 7.2, 2H), 7.44 (tt, J = 7.5, 1.2, IH), 3.27 (q, J= 7.2, 2H), 1.17 (t, J= 7.2, 3H); ESIMS m/z = 281.2 (M+l).
Example 5 Preparation of 2-methoxy-N-(5-phenyl-lH-pyrroloF2,3-blpyridin-3-yl)-acetamide
Following the procedure for Example Id, starting with 3-amino-5-phenyl- lH-pyrrolo[2,3-b]pyridine hydrochloride and methoxyacetyl chloride provided the title compund. 1H ΝMR (400 MHz, CD3OD) δ 8.82 (d, J = 1.9, IH), 8.61 (s, IH), 7.93 (s, IH), 7.72 (d, / = 1.0, 2H), 7.53 (t, / = 7.1, 2H), 7.43 (tt, /= 7.2, 1.2, IH), 4.16 (s, 2H), 3.53 (s, 3H); ESIMS m z = 282.2 (M+l).
Example 6 Preparation of 4-methoxy-N-(5-phenyl- lH-pyrrolor2,3-blρyridin-3-yl)-benzamide
Following the procedure for Example Id, starting with 3-amino-5-phenyl- lH-pyrrolo[2,3-b]pyridine hydrochloride and 4-methoxybenzoyl chloride provided the title compund. 1H ΝMR (400 MHz, CD3OD) δ 8.81 (d, 7 = 1.9, IH), 8.54 (d, J = 1.6, IH), 7.98 (d, J = 6.9, 2H), 7.93 (s, IH), 7.69 (d, /= 8.0, 2H), 7.48 (t, /= 7.8, 2H), 7.39 (t, J= 7.8, IH), 7.02 (d, /= 7.9, 2H); ESIMS m/z = 344.4 (M+l). Example 7
Preparation of N-(5-phenyl-lH-pyrrolor2,3-blρyridin-3-yl)-nicotinamide
Following the procedure for Example Id, starting with 3-amino-5-phenyl- lH-pyrrolo[2,3-b]pyridine hydrochloride and nicotonyl chloride hydrochloride provided the title compund. 1H ΝMR (400 MHz, CD3OD) δ 9.29 (brs, IH), 8.86 (brs, IH), 8.81 (d, 7= 1.8, IH), 8.71 (d, 7 = 2.0, IH), 8.60 (brs, IH), 8.07 (s, IH), 7.86-7.83 (m, IH), 7.74-7.70 (m, 2H), 7.51 (t, 7 = 7.4, 2H), 7.41 (t, 7= 6.8, IH); ESIMS m/z = 315.2 (M+l).
Example 8 Preparation of N-(5-phenyl- lH-pyrrolof 2,3-b]pyridin-3-yl)-isonicotinamide
Following the procedure for Example Id, starting with 3-amino-5-phenyl- lH-pyrrolo[2,3-b]pyridine hydrochloride and isonicotonyl chloride hydrochloride provided the title compund. 1H ΝMR (400 MHz, CD3OD) δ 8.93 (brs, 2H), 8.78 (d, 7= 1.9, IH), 8.61 (brs, IH), 8.31 (d, 7= 5.6, 2H), 8.05 (s, IH), 7.72 (dd, 7= 7.5, 1.4, 2H), 7.51 (t, 7 = 7.3, 2H), 7.42 (tt, 7 = 7.5, 1.2, IH); ESIMS m/z = 315.2 (M+l).
Example 9 Preparation of 4-acetylamino-N-(5-phenyl-lH-pyrrolor2,3-b1pyridin-3-yl)- benzamide
Following the procedure for Example Id, starting with 3-amino-5-phenyl- lH-pyrrolo[2,3-b]pyridine hydrochloride and 4-acetylaminobenzoyl chloride provided the title compund. 1H ΝMR (400 MHz, CD3OD) δ 8.97 (s, IH), 8.63 (s, IH), 8.05-7.97 (m, 3H), 7.76-7.72 (m, 4H), 7.53 (t, 7 = 7.3, 2H), 7.44 (t, 7 = 7.4, IH), 2.17 (s, 3H); ESIMS m/z = 371.2 (M+l).
Example 10 Preparation of 3-dimethylamino-N-(5-phenyl- lH-pyrrolor2,3-blpyridin-3-yl)- benzamide
Following the procedure for Example Id, starting with 3-amino-5-phenyl- lH-pyrrolo[2,3-b]pyridine hydrochloride and 3-dimethylaminobenzoyl chloride provided the title compund. 1H ΝMR (400 MHz, CD3OD) δ 8.96 (d, 7= 1.9, IH), 8.62 (d, 7= 1.6, IH), 8.07 (s, IH), 7.90-7.87 (m, IH), 7.82 (d, 7= 7.0, IH), 7.71 (d, 7= 7.0, 2H), 7.59 (t, 7= 7.9, IH), 7.51 (t, 7 = 7.7, 2H), 7.42 (tt, 7= 7.4, 1.2, IH), 3.21 (s, 6H); ESIMS m/z = 357.4 (M+l).
Example 11 Preparation of acetic acid (5-phenyl-lH-pyrrolo[2,3-blpyridin-3-ylcarbamoyl - methyl ester
Following the procedure for Example Id, starting with 3-amino-5-phenyl- lH-pyrrolo[2,3-b]pyridine hydrochloride and acetoxyacetyl chloride provided the title compund. 1H NMR (400 MHz, CD3OD) δ 8.69 (d, 7= 1.9, IH), 8.57 (s, IH), 7.90 (s, IH), 7.70 (d, 7 = 7.2, 2H), 7.51 (t, 7= 7.9, 2H), 7.42 (t, 7 = 7.3, IH), 4.81 (s, 2H), 2.19 (s, 3H); ESIMS m/z = 310.2 (M+l).
Example 12 Preparation of N-(5-phenyl-lH-pyrrolof2,3-b1pyridin-3-yl)-isobutyramide
Following the procedure for Example Id, starting with 3-amino-5-phenyl- lH-pyrrolo[2,3-b]pyridine hydrochloride and isobutyric anhydride provided the title compund. 1H ΝMR (400, MHz, CD3OD) δ 8.81 (d, 7 = 1.9, IH), 8.59 (d, 7= 1.6, IH), 7.97 (s, IH), 7.73-7.70 (m, 2H), 7.53 (t, 7= 7.3, 2H), 7.44 (tt, 7= 7.4, 1.2, IH), 2.80 (sept, 7= 6.8, IH), 1.26 (d, 7= 6.8, 6H); ESIMS m z = 280.2 (M+l).
Example 13 Preparation of Benzol" 31dioxole-5-carboxylic acid f5-phenyl-lH-pyrrolo[2,3- blpyridin-3-yl)-amide
Following the procedure for Example Id, starting with 3-amino-5-phenyl- lH-pyrrolo[2,3-bjpyridine hydrochloride and piperonyloyl choride provided the title compund. 2Η NMR (400 MHz, CD3S(O)CD3) δ 8.67 (d, 7= 2.1, IH), 8.57 (d, 7 = 2.1, IH), 7.94 (s, IH), 7.76-7.73 (m, 2H), 7.64 (dd, 7 = 8.1, 1.8, IH), 7.58 (d, 7= 1.7, IH), 7.52 (t, 7= 7.3, 2H), 7.38 (t, 7= 7.4, IH), 7.08 (d, 7= 8.2, IH), 6.14 (s, 2H); ESIMS m/z = 358.2 (M+l).
Example 14 Preparation of Pyrazine-2-carboxylic acid (5-phenyl-lH-pyrrolor2,3-b1pyridin-3-yl)- amide Following the procedure for Example Id, starting with 3-amino-5-phenyl- lH-pyrrolo[2,3-b]pyridine hydrochloride and pyrazine-2-carbonyl chloride provided the title compund. ESIMS m/z = 315.2 (M+).
Example 15 Preparation of Thiophene-2-carboxylic acid (5-phenyl-lH-pyrrolor2 3-b1pyridin-3- yl)-amide
Following the procedure for Example Id, starting with 3-amino-5-phenyl- lH-pyrrolo[2,3-b]pyridine hydrochloride and thiophene-2-carbonyl chloride provided the title compund. 1H NMR (400 MHz, CD3OD) δ 8.82 (d, 7 = 1.9, IH), 8.58 (d, 7= 1.6, IH), 7.97 (dd, 7= 3.7, 1.0, IH), 7.94 (s, IH), 7.75 (dd, 7= 5.0, 1.1, IH), 7.74-7.70 (m, 2H), 7.53-7.48 (m, 2H), 7.42 (tt, 7= 7.4, 1.2, IH), 7.21 (dd, 7 = 5.0, 3.8, IH); ESIMS m/z = 320.0 (M+l).
Example 16 Preparation of (lH-pyrrolor2,3-b1pyridin-3-yl -nicotinamide
Following the procedure for Example Id, starting with 3-amino-lH- pyrrolo[2,3-b]pyridine hydrochloride and nicotonyl chloride hydrochloride provided the title compund. 1H NMR (400 MHz, CD3OD) δ 9.29 (d, 7= 2.0, IH), 8.88 (dd, 7 = 5.2, 1.5, IH), 8.79 (dd, 7= 8.0, 1.2, IH), 8.74 (dt, 7 = 8.0, 2.0, IH), 8.42 (d, 7= 4.6, IH), 8.13 (s, IH), 7.87 (ddd, 7= 8.0, 5.3, 0.6, IH), 7.49 (dd, 7= 8.0, 5.6, IH).
Example 17 Preparation of N-(5-(3-acetamido-phenyl)- lH-pyrroloF2,3-b]pyridin-3-yl)- butyramide
a) 3-amino-5-bromo-lH-pyrrolo[2,3-b]pyridine
5-Bromo-3-nitro-lH-pyrrolo[2,3-b]pyridine (4.5 g, 18.5 mmol, 1.0 equiv) was dissolved in glacial acetic acid (160 mL) at 85 °C, and a solution of tin(II) chloride dihydrate (17.5g, 92.5 mmol, 5.0 equiv) in cone, hydrochloric acid (18 mL) was added over 10 min. The mixture was stirred at 85 °C for 1 h, then cooled, poured into ice water and made basic by addition of 50% ΝaOΗ. The basic aqueous phase was then extracted with CΗ2C12, the organic extracts were combined, dried (MgSO4) and concentrated to give 2.4 g (61%) of the title compound. . Η ΝMR (400 MHz, CD3S(O)CD3) δ 10.87 (s, IH), 8.16 (d, 7= 2.0, IH), 8.13 (d, 7= 2.1, IH), 6.72 (d, 7 = 2.1, IH), 4.40 (br s, 2H); ESIMS m/z = 212.0, 214.0 (M+l).
b) N-(5-bromo-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide
Butyric anhydride (1.16 mL, 7.1 mmol, 1.0 equiv) was added to a solution of 3-amino-5-bromo-lH-pyrrolo[2,3-b]pyridine (1.50 g, 7.1 mmol, 1 equiv) in CΗ2CL, (10 mL) and pyridine (5 mL). The mixture was stirred at rt for 2 h, then the volatiles were removed and the residue was partitioned between H2O and EtOAc. The aqueous layer was extracted with EtOAc, the combined organic layers were washed with brine, dried over MgSO4 and concentrated to give a solid which was triturated with EtOAc to provide 1.31 g (65%) of the title compound. Η ΝMR (400 MHz, CD3S(O)CD3) δ 9.92 (s, IH), 8.42 (d, 7= 2.1, IH), 8.26 (d, 7= 2.1, IH), 7.81 (d, 7 = 2.4, IH), 2.33 (t, 7 = 7.4, 2H), 1.64 (sext, 7 = 7.4, 2H), 0.93 (t, 7 = 7.3, 2H); ESIMS m/z = 282.0, 284.0 (M+l).
c) N-(5-(3-acetamide-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide
N-(5-Bromo-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide (28 mg, 0.1 mmol, 1.0 equiv), tetrakis(triphenylphosphine)palladium (5.8 mg, 0.005 mmol, 0.05 equiv) and 3-acetamidobenzeneboronic acid (26.8 mg, 0.15 mmol, 1.5 equiv) were combined in 2/1/1 DMF/EtOΗ/aq. 2M K2CO3 (0.75 mL) and the mixture was heated to 100 °C for 15 h. The reaction mixture was cooled, concentrated, and the residue was purified by reverse phase ΗPLC to give the title compound. !Η ΝMR (400 MHz, CD3S(O)CD3) δ 8.81 (d, 7= 1.8, IH), 8.56 (s, IH), 8.06 (s, IH), 7.98 (s, IH), 7.43-7.38 (m, 3H), 2.47 (t, 7 = 7.3, 2H), 2.17 (s, 3H), 1.78 (sext, 7 = 7.4, 2H), 1.04 (t 7 = 7.4, 3H).
Example 18
Preparation of N-(5-(4-carboxy-phenyl)- lH-pyrrolor2,3-b1pyridin-3-yl -butyramide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-butyramide and 4-carboxybenzeneboronic acid provided the title compund. !Η ΝMR (400 MHz, CD3S(O)CD3) δ 10.04 (s, IH), 8.63 (s, 2H), 8.07 (d, 7= 8.6, 2H), 7.87-7.83 (m, 3H), 2.37 (t, 7 = 7.3, 2H), 1.66 (sext, 7 = 7.3, 2H), 0.95 (t, 7= 7.3, 3H).
Example 19 Preparation of N-(5-f4-dimethylamino-phenylV lH-pyrrolor2,3-b1pyridin-3-yl)- butyr amide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-butyramide and 4-dimethylaminobenzeneboronic acid provided the title compund. 1H ΝMR (400 MHz, CD3S(O)CD3) δ 11.7 (s, IH), 10.09 (s, IH), 8.66 (s, IH), 5.58 (s, IH), 7.89 (d, 7 = 2.2, IH), 7.69 (d, 7= 8.7, 2H), 7.17 (d, 7= 8.4, 2H), 2.38(t, 7= 7.3, 2H), 1.66 (sext, 7= 7.3, 2H), 0.95 (t, 7 = 7.3, 3H).
Example 20 Preparation of N-(5-(3-hydroxymethyl-phenyl -lH-pyrrolor2,3-blpyridin-3-yl)- butyr amide
Following the procedure for Example 17c, starting fromN-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-butyramide and 3-hydroxymethylbenzeneboronic acid provided the title compund. 1H ΝMR (400 MHz, CD3S(O)CD3) δ 10.07 (s, IH), 8.61 (d, 7 = 2.0, IH), 8.57 (d, 7 = 2.0, IH), 7.87 (d, 7= 2.4, IH), 7.69 (s, IH), 7.59 (d, 7= 7.8, IH), 7.46 (t, 7= 7.7, IH), 7.33 (d, 7= 7.6, IH), 2.38 (t, 7 = 7.3, 2H), 1.66 (sext, 7 = 7.3, 2H), 0.95 (t, 7 = 7.3, 3H).
Example 21
Preparation of N-(5-(4-acetyl-phenyl)- lH-pyrrolo[2,3-b1pyridin-3-yl)-butyramide Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-butyramide and 4-acetylbenzeneboronic acid provided the title compund. 1H ΝMR (400 MHz, CD3S(O)CD3) δ 10.04 (s, IH), 8.64 (s, IH), 8.63 (s, IH), 8.09 (d, 7= 8.4, 2H), 7.89-7.85 (m, 3H), 2.38 (d, 7= 7.3, 2H), 1.68 (d, 7 = 7.3, 2H), 0.95 (t, 7 = 7.3, 3H).
Example 22 Preparation of N-(5-(3-methyl-phenyl)-lH-pyrroloF2,3-blpyridin-3-yl)-butyr amide Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-butyramide and 3-methylbenzeneboronic acid provided the title compund. 1H ΝMR (400 MHz, CD3OD) δ 8.84 (d, 7 = 1.8, IH), 8.57 (d, 7 = 1.7, IH), 7.98 (s, IH), 7.53-7.45 (m, 2H), 7.37 (t, 7 = 7.6, IH), 7.25 (d, 7 = 7.4, IH), 2.47 (t, 7 = 7.3, 2H), 2.44 (s, 3H), 1.78 (sext, 7= 7.3, 2H), 1.04 (t, 7= 7.3, 3H).
Example 23 Preparation of N-(5-(3-fluoro-phenyl - lH-pyrrolor2.3-b1pyridin-3-yl -butyramide
Following the procedure for Example 17c, starting from N-(5-lH-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-butyramide and 3-fluorobenzeneboronic acid provided the title compund. 1H ΝMR (400 MHz, CD3OD) δ 8.74 (d, 7= 1.9, IH), 8.59 (d, 7 = 1.9, IH), 7.95 (s, IH), 7.55-7.45 (m, 3H), 7.20-7.12 (m, IH), 2.47 (t, 7 = 7.3, 2H), 1.78 (d, 7= 7.3, 2H), 1.04 (t, 7= 7.3, 3H).
Example 24 Preparation ofN-(5-(3-chloro-phenyl)-pyrrolor2,3-blpyridin-3-yl)-butyramide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-butyramide and 3-chlorobenzeneboronic acid provided the title compund. 1H ΝMR (400 MHz, CD3OD) δ 8.68 (d, 7 = 2.0, IH), 8.56 (d, 7 = 1.9, IH), 7.93 (s, IH), 7.74 (t, 7 = 1.9, IH), 7.64 (ddd, 7 = 7.7, 1.6, 1.1, IH), 7.50 (t, 7 = 7.9, IH), 7.42 (ddd, 7 = 8.0, 2.0, 1.1, IH), 2.47 (t, 7 = 7.3, 2H), 1.78 (sext, 7 = 7.3, IH), 1.04 (t, 7 = 7.3, IH); ESIMS m/z = 314.2 (M+l).
Example 25 Preparation of N-(5-(4-hydroxy-phenyl)-lH-pyrrolor2,3-blpyridin-3-yl)-butyr amide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-butyramide and 4-hydroxybenzeneboronic acid provided the title compund. 1H ΝMR (400 MHz, CD3OD) δ 8.89 (d, 7 = 1.8, IH), 8.55 (d, 7 =1.8, IH), 8.00 (s, IH), 7.56-7.53 (m, 2H), 6.97-6.93 (m, 2H), 2.48 (t, 7 = 7.3, 2H), 1.78 (sext, 7 = 7.3, 2H), 1.04 (t, 7 = 7.3, 3H); ESIMS m/z = 296.2 (M+l).
Example 26 Preparation of N-(5-(4-cyano-phenyl)- lH-pyrrolo[2,3-b1pyridin-3-yl)-butyramide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-butyramide and 4-cyanobenzeneboronic acid provided the title compund. 1H NMR (400 MHz, CD3OD) δ 8.66 (s, IH), 8.60 (s, IH), 7.92- 7.83 (m, 5H), 2.47 (t, 7 = 7.3, 2H), 1.78 (sext, 7 = 7.3, 2H), 1.04 (t, 7 = 7.3, 3H); ESIMS m/z = 305.2 (M+l).
Example 27 Preparation of N-(5-(pyridin-3-yl)- lH-pyrrolor2.3-b1pyridin-3-yl)-butyramide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-butyramide and pyridine-3 -boronic acid provided the title compund. 1H ΝMR (400 MHz, CD3S(O)CD3) δ 10.03 (s, IH), 9.10 (d, 7 = 2.0, IH), 8.75-8.71 (m, IH), 8.65 (d, 7 = 2.2, IH), 8.60 (d, 7 = 2.0, IH), 7.87-7.77 (m, 2H), 2.37 (t, 7 = 7.3, 2H), 1.66 (sext, 7 = 7.3, 2H), 0.95 (t, 7 = 7.3, 3H); ESIMS m z = 281.2 (M+l).
Example 28 Preparation of N-f 5-(pyridin-4-yl)- lH-pyrrolor2.3-blpyridin-3-yl)-butyramide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-butyramide and pyridine-4-boronic acid provided the title compund. !Η ΝMR (400 MHz, CD3S(O)CD3) δ 8.86-8.82 (m, 3H), 8.78 (d, 7 = 2.2, IH), 8.43 (d, 7 = 7.0, 2H), 7.85 (s, IH), 2.49 (t, 7 = 7.3, 2H), 1.79 (sext, 7 = 7.3, 2H), 1.05 (t, 7= 7.3, 3H); ESIMS m/z = 281.2 (M+l).
Example 29 Preparation of N-(5-(3-carboxy-phenyl)-lH-pyrrolor2,3-blpyridin-3-yl)-butyr amide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-bjpyridin-3-yl)-butyramide and 3-carboxybenzeneboronic acid provided the title compund. 1H ΝMR (400 MHz, CD3S(O)CD3) δ 10.08 (s, IH), 8.63 (s, IH), 8.60 (s, IH), 8.29 (t, 7 = 1.7, IH), 8.01-7.95 (m, 2H), 7.95 (s, IH), 7.64 (t, 7 = 7.8, IH), 2.36 (t, 7 = 7.3, 2H), 1.66 (sext, 7= 7.3, 2H), 0.95 (t, 7= 7.3, 3H); ESIMS m/z = 324.2 (M+l).
Example 30 Preparation of N-(5-(4-methylsulfonyl-phenyl)-lH-pyrrolor2,3-blpyridin-3-yl)- butyr amide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-butyramide and 4-methylsulfonylbenzeneboronic acid provided the title compund. 1H NMR (400 MHz, CD3OD) δ 8.81 (d, 7 = 2.0, IH), 8.69 (d, 7 = 1.9, IH), 8.11 (d, 7 = 6.6, 2H), 8.01-7.97 (m, 3H), 2.48 (t, 7 = 7.3, 2H), 1.78 (sext, 7 = 7.3, 2H), 1.05 (t, 7 = 7.3, 3H); ESIMS m/z = 358.4 (M+l).
Example 31 Preparation of N-(5-(4-chloro-phenyl - lH-pyrrolor2,3-b1pyridin-3-yl)-butyramide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-butyramide and 4-chlorobenzeneboronic acid provided the title compund. 1H ΝMR (400 MHz, CD3OD) δ 8.65 (d, 7 = 2.0, IH), 8.55 (d, 7 = 2.0, IH), 7.92 (s, IH), 7.70-7.50 (m, 5H), 2.46 (t, 7 = 7.3, 2H), 1.77 (sext, 7 = 7.3, 2H), 1.04 (t, 7= 7.3, 3H); ESIMS m/z = 314.2 (M+l).
Example 32 Preparation of N-(5-(4-hvdroxymethyl-phenyl)-lH-pyrrolor2,3-blpyridin-3-yl)- butyramide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-butyramide and 4-hydroxymethylbenzeneboronic acid provided the title compund. 1H ΝMR (400 MHz, CD3OD) δ 8.88 (d, 7 = 1.9, IH), 8.62 (d 7 = 1.7, IH), 8.00 (s, IH), 7.72 (d, 7 = 8.3, 2H), 7.54 (d, 7 = 8.1, 2H), 4.70 (s, 2H), 2.48 (t, 7 = 7.3, 2H), 1.79 (sext, 7 = 7.3, 2H), 1.05 (t, 7 = 7.3, 3H); ESIMS m/z = 310.2 (M+l).
Example 33 Preparation of N-(5-(3 ,4-dimethoxy-phenyl)- lH-pyrrolor2,3-blpyridin-3-yl)- butyr amide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-butyramide and 3,4-dimethoxybenzeneboronic acid provided the title compund. 1H ΝMR (400 MHz, CD3CΝ) δ 8.79 (d, 7 = 1.7, IH), 8.72 (s, IH), 8.53 (d, 7 = 1.7, IH), 8.01 (s, IH), 7.78 (brs, IH), 7.21 (s, IH), 7.18 (d, 7 = 8.0, IH), 7.05 (d, 7 = 8.7, IH), 3.91 (s, 3H), 3.87 (s, 3H), 2.45 (t, 7 = 7.3, 2H), 1.76 (sext, 7= 7.3, 2H), 1.03 (t, 7 = 7.3, 3H); ESIMS m/z = 340.4 (M+l).
Example 34 Preparation of N-(5-(thiophen-3-yl)-lH-pyrrolor2.3-b]pyridin-3-yl)-butyramide a) N-(5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH-pyrrolo[3,2-b]pyridin-3- yl)-butyr amide
N-(5-Bromo-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide (500 mg, 1.8 mmol, 1.0 equiv), bis(pinacolato)diboron (450 mg, 1.8 mmol, 1.0 equiv) and potassium acetate (521 mg, 5.3 mmol, 3.0 equiv) were dissolved in DMSO (10 mL) and the solution was degassed. Solid PdCl (dppf) (41 mg, 0.05 mmol, 0.03 equiv) was added and the mixture was heated to 100 °C for 16 h. The reaction mixture was then cool, poured into Η2O and EtOAc and filtered through Celite. The aqueous phase was extracted with EtOAc, the combined organic extracts were washed with H2O and brine, dried over MgSO and concentrated to give a brown solid which was triturated with EtOAc to provide 210 mg (36%) the title compound. . 1H ΝMR (400 MHz, CD3S(O)CD3) δ 10.06 (s, IH), 8.62 (s, IH), 8.44 (d, 7= 1.4, IH), 7.79 (d, 7 = 1.3, IH), 2.34 (t, 7 = 7.3, 2H), 1.63 (sext, 7 = 7.4, 2H), 1.33 (s, 12H), 0.93 (t, 7 = 7.3, 3H).
b) N-(5-(thiophen-3-yl)-lH-pyrroIo[2,3-b]pyridin-3-yl)-butyramide
N-(5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH-pyrrolo[3,2- b]pyridin-3-yl)-butyramide (36 mg, 0.1 mmol, 1.0 equiv), tetrakis(triphenylphosphine)palladium (5.8 mg, 0.005 mmol, 0.05 equiv) and 3- bromothiophene (15 μL, 0.15 mmol, 1.5 equiv) were combined in 2/1/1 DMF/EtOΗ/aq. 2M K2CO3 (0.75 mL) and the mixture was heated to 100 °C for 15 h. The reaction mixture was cooled, concentrated, and the residue was purified by reverse phase ΗPLC to give the title compound. 1H ΝMR (400 MHz, CD3OD) δ 8.89 (d, 7 = 1.8, IH), 8.67 (s, IH), 7.97 (s, IH), 7.81-7.78 (m, IH), 7.61 (dd, 7 = 5.0, 2.9, IH), 7.56 (dd, 7= 5.0, 1.4, IH), 2.48 (t, 7= 7.3, 2H), 1.78 (sext, 7 = 7.3, 2H), 1.04 (t, 7= 7.3, 3H), ESLMS m/z = 286.0 (M+l).
Example 35 Preparation of N-(5-(3-aminophenyl)-lH-pyrrolo[2,3-blρyridm-3-yl)-butyramide
Following the procedure for Example 34b, starting from N-(5-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH-pyrrolo[3,2-b]pyridin-3-yl)-butyr amide and 3-bromoaniline provided the title compund. !Η ΝMR (400 MHz, CD3OD) δ 8.68 (d, 7 = 2.0, IH), 8.58 (d, 7 = 2.0, IH), 7.89 (s, IH), 7.83-7.80 (m, IH), 7.73- 7.65 (m, 2H), 7.45-7.40 (m, IH), 2.47 (t, 7 = 7.3, 2H), 1.78 (sext, 7 = 7.3, 2H), 1.04 (t, 7 = 7.3, 3H); ESIMS m/z = 295.2 (M+l).
Example 36 Preparation of N-(5-(4-aminomethylphenyl)-lH-pyrrolor2,3-b1pyridin-3-yl)- butyramide
Following the procedure for Example 34b, starting from N-(5-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH-pyrrolo[3,2-b]pyridin-3-yl)-butyramide and 4-bromobenzylamine provided the title compund. 1H ΝMR (400 MHz, CD3OD) δ 8.75 (d, 7 = 1.9, IH), 8.60 (d, 7 = 1.8, IH), 7.92 (s, IH), 7.81 (d, 7 = 8.3, 2H), 7.61 (d, 7= 8.2, 2H), 4.20 (s, 2H), 2.47 (t, 7 = 7.3, 2H), 1.78 (sext, 7 = 7.3, 2H), 1.04 (t, 7 = 7.3, 3H); ESIMS m/z = 309.4 (M+l).
Example 37 Preparation of N-(5-(3-sulfamoylphenyl)-lH-pyrrolor2,3-b1pyridin-3-yl)-butyramide Following the procedure for Example 34b, starting from N-(5-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH-pyrrolo[3,2-b]pyridin-3-yl)-butyramide and 3-bromobenzenesulfonamide provided the title compund. 1H ΝMR (400 MHz, CD3S(O) CD3) δ 10.10 (s, IH), 8.59 (s, 2H), 8.17 (s, IH), 7.96 (d, 7= 7.8, IH), 7.87 (d, 7 = 2.4, IH), 7.83 (d, 7 = 7.9, IH), 7.71 (t, 7 = 7.8, IH), 7.44 (s, IH), 2.38 (t, 7 = 7.3, 2H), 1.66 (sext, 7= 7.3, 2H), 0.95 (t, 7 = 7.3, 3H); ESIMS m/z = 359.2 (M+l).
Example 38 Preparation of N-(5-(4-sulfamoylphenyl)- lH-pyrrolor2,3-blpyridin-3-yl)-butyramide Following the procedure for Example 34b, starting from N-(5-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH-pyrrolo[3,2-b]pyridin-3-yl)-butyr amide and 4-bromobenzenesulfonamide provided the title compund. 1H ΝMR (400 MHz, CD3S(O) CD3) δ 10.02 (s, IH), 8.61 (d, 7 = 2.1, IH), 8.58 (d, 7 = 2.1, IH), 7.96-7.91 ( , 4H), 7.85 (d, 7= 2.4, IH), 7.41 (s, 2H), 2.37 (t, 7= 7.3, 2H), 1.66 (sext, 7 = 7.3, 2H), 0.95 (t, 7 = 7.3, 3H); ESIMS m/z = 359.2 (M+l).
Example 39 Preparation of N-(5-(3-acetamido-phenyl)-lH-pyrrolor2,3-b1pyridin-3-yl)- nicotinamide a) N-(5-bromo-lH-pyrrolo[3,2-b]pyridin-3-yl)-nicotinamide
Following the procedure for Example 17b starting from 3-amino-5-bromo~ lH-pyrrolo[2,3-b]pyridine and nicotinoyl chloride hydrochloride provided the title compound. 1H ΝMR (400 MHz, CD3S(O)CD3) δ 10.53 (s, IH), 9.16 (d, 7= 1.7, IH), 8.77 (dd, 7= 4.8, 2.0, IH), 8.61 (d, 7= 2.1, IH), 8.36-8.30 (m, 2H), 7.99 (d, 7 = 2.6, IH), 7.61-7.57 (m, IH).
b) N-(5-(3-acetamido-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and 3-acetamidobenzeneboronic acid provided the title compund. Η ΝMR (400 MHz, CD3S(O)CD3) δ 10.68 (s, IH), 10.07 (s, IH), 9.21 (d, 7 = 2.0, IH), 8.82 (d, 7 = 4.9, IH), 8.61 (d, 7= 2.1, IH), 8.52 (d, 7 = 2.0, IH), 8.44 (d, 7= 8.0, IH), 7.97 (d, 7= 9.1, IH), 7.68 (dd, 7= 7.8, 5.0, IH), 7.56-7.53 (m, IH), 7.44-7.37 (m, IH).
Example 40 Preparation of N-(5-(4-hydroxymethyl-phenyl)- lH-pyrrolor2,3-b1pyridin-3-yl)- nicotinamide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and 4-hydroxymethylbenzeneboronic acid provided the title compund. Η ΝMR (400 MHz, CD3S(O)CD3) δ 10.66 (s, IH), 9.25 (d, 7= 1.7, IH), 8.84 (dd, 7= 5.0, 1.6, IH), 8.67 (d, 7 = 2.0, IH), 8.59 (d, 7= 2.2, IH), 8.47 (d, 7 = 8.0, IH), 8.00 (d, 7= 2.5, IH), 7.72 (dd, 7 = 4.1, 2.2, 2H), 7.45 (d, 7 = 8.2, 2H), 4.57 (s, 2H).
Example 41 Preparation of N-(5-(4-dimethylamino-phenyl)- lH-pyrrolor2 3-b1pyridin-3-yl)- nicotinamide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and 4-dimethylaminobenzeneboronic acid provided the title compund. Η ΝMR (400 MHz, CD3S(O)CD3) δ 10.61 (s, IH), 9.21 (d, 7= 1.7, IH), 8.82 (dd, 7 = 4.9, 1.5, IH), 8.60 (d, 7 = 2.0, IH), 8.54 (d, 7= 2.1, IH), 8.45-8.41 (m, IH), 7.96 (d, 7 = 2.5, IH), 7.70-7.61 (m, 3H), 2.99 (s, 6H).
Example 42 Preparation ofN-(5-f3,4-dimethoxy-phenyl)-lH-pyrrolor2,3-blpyridin-3-yl)- nicotinamide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and 3,4-dimethoxybenzeneboronic acid provided the title compund. Η ΝMR (400 MHz, CD3S(O)CD3) δ 10.56 (s, IH), 9.19 (d, 7= 1.7, IH), 8.77 (dd, 7= 4.8, 1.4, IH), 8.59-8.55 (m, 2H), 8.36 (dt, 7= 8.0, 1.8, IH), 7.97 (s, IH), 7.60 (dd, 7= 8.5, 3.8, IH), 7.28 (d, 7= 2.0, IH), 7.26-7.22 (m, 2H), 7.08 (d, 7 = 8.3, IH), 3.88 (s, 3H), 3.81 (s, 3H).
Example 43 Preparation of N-(5-(3,4-(methylenedioxy)-phenyl)-lH-pyrrolor2,3-b1pyridin-3-yl)- nicotinamide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and 3,4-(methylenedioxy)benzeneboronic acid provided the title compund. Η ΝMR (400 MHz, CD3S(O)CD3) δ 10.53 (s, IH), 9.18 (s, IH), 8.80-8.75 (m, IH), 8.57 (d, 7= 2.0, IH), 8.52 (d, 7= 2.1, IH), 8.35 (dt, 7 = 10.0, 2.0, IH), 7.96 (d, 7 = 2.5, IH), 7.69 (dd, 7 = 7.8, 4.8, IH), 7.31 (d, 7 = 1.7, IH), 7.20 (dd, 7 = 8.1, 1.8, IH), 7.05 (d, 7 = 8.0, IH), 6.08 (s, 2H).
Example 44 Preparation of N-(5-(thiophen-3-yl)-lH-pyrrolor2,3-b]pyridin-3-yl)-nicotinamide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and thiophene-3 -boronic acid provided the title compund. Η ΝMR (400 MHz, CD3OD) δ 9.28 (dd, 7= 2.0, 0.6, IH), 8.86 (dd, 7= 5.2, 1.6, IH), 8.81 (d, 7= 1.9, IH), 8.70 (dt, 7= 7.2, 1.8, IH), 8.66 (d, 7= 1.1, IH), 8.04 (s, IH), 7.86-7.81 (m, IH), 7.75 (dd, 7= 2.8, 1.4, IH), 7.59-7.55 (m, 2H).
Example 45 Preparation of N-(5-(4-aminophenyl)- lH-pyrrolor2,3-blpyridin-3-yl)-nicotinamide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3~b]pyridin-3-yl)-nicotinamide and 4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)aniline provided the title compund. Η NMR (400 MHz, CD3OD) δ 9.36 (d, 7 = 1.8, IH), 8.94-8.89 (m, 2H), 8.83 (d, 7= 2.0, IH), 8.64 (d, 7 = 2.0, IH), 8.07 (s, IH), 8.00 (ddd, 7= 8.1, 5.5, 0.7, IH), 7.88 (dt, 7= 8.3, 0.9, 2H), 7.53 (dt, 7 = 8.5, 1.8, 2H); ESIMS m z = 330.4 (M+l).
Example 46 Preparation of N-(5-(4-hydroxy-3-methoxy-phenyl)- lH-pyrrolor2,3-blpyridin-3-yl)- nicotinamide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and 3-methoxy-4-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)phenol provided the title compund. Η ΝMR (400 MHz, CD3OD) δ 9.26 (s, IH), 8.86-8.83 (m, 2H), 8.66 (dt, 7= 8.0, 1.8, IH), 8.57 (s, IH), 8.10 (s, IH), 7.82 (dd, 7= 8.0, 4.8, IH), 7.27 (d, 7= 2.0, IH), 7.16 (dd, 7= 8.2, 2.1, IH), 6.94 (d, 7= 8.2, IH), 3.96 (s, 3H); ESIMS m/z = 361.2 (M+l)
Example 47 Preparation of N-(5-(3,5-dimethyl-4-hydroxy-phenyl)-lH-pyrrolor2,3-blpyridin-3- yl)-nicotinamide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and 3,5-dimethyl-4-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)phenol provided the title compund. Η ΝMR (400 MHz, CD3OD) δ 9.26 (s, IH), 8.90 (d, 7 = 1.9, IH), 8.85 (br d, 7 = 4.0, IH), 8.68 (dt, 7 = 8.1, 2.0, IH), 8.55 (d, 7= 1.6, IH), 8.09 (s, IH), 7.83 (dd, 7= 8.0, 5.2, IH), 7.30 (s, 2H), 2.30 (s, 6H); ESIMS m/z = 359.2 (M+l).
Example 48 Preparation of N-(5-(naphthalen-2-yl)- lH-pyrrolor2.3-b1pyridin-3-yl)-nicotinamide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and naphthalene-2-boronic acid provided the title compund. Η ΝMR (400 MHz, CD3S(O)CD3) δ 10 71 (s, IH), 9.26 (d, 7 = 2.0, IH), 8.86-8.83 (m, 2H), 8.76 (d, 7= 2.0, IH), 8.51 (dt, 7= 8.0, 1.4, IH), 8.29 (s, IH), 8.06-7.93 (m, 5H), 7.72 (dd, 7= 7.9, 5.0, IH), 7.59-7.52 (m, 2H); ESIMS m/z = 365.2 (M+l). Example 49
Preparation of N-(5-(4-methoxyphenyl)-lH-pyrrolo[213-b1pyridin-3-yl)-nicotinamide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and 4-methoxybenzeneboronic acid provided the title compund. Η ΝMR (400 MHz, CD3OD) δ 9.33 (d, 7= 2.0, IH), 8.93-8.88 (m, 2H), 8.82 (dt, 7= 8.0, 2.0, IH), 8.56 (d, 7 = 1.8, IH), 8.09 (s, IH), 7.93 (dd, 7= 7.9, 5.3, IH), 7.62 (d, 7 = 8.8, 2H), 7.03 (d, 7= 8.8, 2H), 3.84 (s, 3H); ESIMS m/z = 345.2 (M+l).
Example 50 Preparation of pyridine-2-carboxylic acid (5-phenyl-lH-pyrrolo[2.3-b1pyridin-3-yl)- amide
3-Amino-5-phenyl-lH-pyrrolo[2,3-b]pyridine (42 mg, 0.2 mmol, 1.0 equiv), pyridine-2-carboxylic acid (24 mg, 0.2 mmol, 1.0 equiv) and Et3Ν (84 μL, 0.6 mmol, 3.0 equiv) were combined in DMF (1 mL). BOP reagent (106 mg, 0.24 mmol, 1.2 equiv) was added and the mixture was stirred at rt for 16 h. The reaction mixture was then poured into Η2O and extracted with EtOAc. The combined organic extracts were washed with H2O and brine, dried over MgSO and concentrated. The reside was purified by reverse-phase HPLC to give 36 mg (57%) of the title compound. 1H NMR (400 MHz, CD3S(O)CD3) δ 10.85 (s, IH), 8.84-8.78 (m, 2H), 8.61 (d, 7 = 2.0, IH), 8.21-8.16 (m, IH), 8.13-7.95 (m, 2H), 7.78 (m, 2H), 7.71-7.65 (m, IH), 7.55-7.49 (m, IH), 7.41-7.37 (m, IH).
Example 51 Preparation of 4-methyl-N-(5-phenyl-lH-pyrrolor2,3-b1pyridin-3-yl)-nicotinamide Following the procedure for Example 50, starting from 3-amino-5-phenyl- lH-pyrrolo[2,3-b]pyridine and 4-methylnicotinic acid provided the title compund. 1H ΝMR (400 MHz, CD3S(O)CD3) δ 9.08 (s, IH), 8.79 (d, 7 = 5.9, IH), 8.69 (d, 7 = 1.9, IH), 8.61 (s, IH), 8.15 (s, IH), 7.98 (d, 7 = 5.9, IH), 7.70 (d, 7 = 8.0, 2H), 7.51 (t, 7 = 7.3, 2H), 7.42 (t, 7= 7.5, IH), 2.78 (s, 3H); ESIMS m/z = 329.4 (M+l).
Example 52 Preparation of 6-methyl-N-(5-phenyl-lH-pyrrolor2.3-b1pyridin-3-yl)-nicotinamide Following the procedure for Example 50, starting from 3-amino-5-phenyl- lH-pyrrolo[2,3-b]pyridine and 6-methylnicotinic acid provided the title compund. 1H NMR (400 MHz, CD3S(O)CD3) δ 9.25 (d, 7= 1.8, IH), 8.90 (dd, 7= 8.3, 2.9, IH), 8.79 (d, 7= 2.1, IH), 8.61 (s, IH), 8.08 (s, IH), 7.96 (d, 7 = 8.3, IH), 7.74 (d, 7 = 8.0, 2H), 7.52 (t, 7 = 7.3, 2H), 7.42 (t, 7 = 7.5, IH), 2.84 (s, 3H); ESIMS m/z = 329.2 (M+l).
Example 53 Preparation of 3-hvdroxy-N-(5-phenyl-lH-pyrrolor2.3-b1pyridin-3-yl)-benzamide
Following the procedure for Example 50, starting from 3-amino-5-phenyl- lH-pyrrolo[2,3-b]pyridine and 3-hydroxybenzoic acid provided the title compund. 1Η ΝMR (400 MΗz, CD3S(O)CD3) δ 8.91 (d, 7 = 1.8, IH), 8.62 (s, IH), 8.04 (s, IH), 7.76-7.3 (m, 2H), 7.55-7.40 (m, 5H), 7.35 (t, 7= 7.9, IH), 7.04-7.01 (m, IH); ESIMS m/z = 330.4 (M+l).
Example 54 Preparation of 6-(2-(pyrrolidin-l-yl)ethyl-N-(5-phenyl-lH-pyrrolor2,3-b1pyridin-3- yl)-nicotinamide
Following the procedure for Example 50, starting from 3-amino-5-phenyl- lH-pyrrolo[2,3-bjpyridine and 6-(2-pyrrolidin-l-yl)ethyl)pyridine carboxylic acid provided the title compund. 1H ΝMR (400 MHz, CD3S(O)CD3) δ 9.44 (d, 7 = 1.6, IH), 9.41 (s, IH), 8.91 (d, 7 = 7.8, IH), 8.77 (s, IH), 8.28 (s, IH), 8.03 (d, 7 = 8.2, IH), 7.90-7.75 (m, 2H), 7.60-7.45 (m, 3H), 3.82-3.75 (m, 4H), 3.61-3.55 (m, 2H), 3.27-3.20 (m, 2H), 2.25-2.19 (m, 2H), 2.15-2.08 (m, 2H).
Example 55 Preparation of N- 5-(3-formylphenyl- lH-pyrrolor2,3-b1pyridin-3-yl)-butyramide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-butyramide and 3-formylbenzeneboronic acid provided the title compound. ESIMS m/z = 308.2 (M+l).
Example 56 Preparation of N-(5-(4-formylphenyl- lΗ-pyrrolor23-b1pyridin-3-yl)-butyramide Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-butyramide and 4-formylbenzeneboronic acid provided the title compound. ESIMS m/z = 308.2 (M+l).
Example 57 Preparation of N-(5-(3-formylphenyl- lΗ-pyrrolor2,3-b1p idin-3-yl)-nicotinamide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and 3-formylbenzeneboronic acid provided the title compound. ESIMS m/z = 343.2 (M+l).
Example 58 Preparation ofN-(5-(4-formylphenyl-lΗ-pyrrolor2,3-b1pyridin-3-yl)-nicotinamide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and 4-formylbenzeneboronic acid provided the title compound. ESIMS m/z = 343.0 (M+l).
Example 59 Preparation of N-(5-(4-dimethylaminomethyl-phenyl- lΗ-pyrroloF2,3-b1pyridin-3- yl)-nicotinamide
N-(5-(4-formylphenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide (51 mg, 0.15 mmol, 1.0 equiv) and dimethylamine hydrochloride (61 mg, 0.75 mmol, 5 equiv) were combind in MeOH (1.5 mL). Glacial acetic acid (86 uL, 1.5 mmol, 10 equiv) was added, followed by sodium cyanoborohydride (38 mg, 0.6 mmol, 4.0 equiv) and the mixture heated to reflux for 5 h. The reaction mixture was cooled and concentrated and the residue purified by preparative HPLC to give the title compound. ESIMS m/z = 372.2 (M+l).
Example 60 Preparation of N-(5-(4-morpholinomethyl-phenyl-lH-pyrrolor2,3-b1pyridin-3-yl)- nicotinamide
Following the procedure for Example 59, starting from N-(5-(4- formylphenyl-lH-pyrrolo[2,3-b]ρyridin-3-yl)-nicotinamide and morpholine provided the title compound. ESIMS m/z = 414.2 (M+l).
Example 61 Preparation of N-(5-(4-(4-methylpiperazino)-methyl-phenyl-lH-pyrroloF2,3- blpyridin-3-yl)-nicotinamide
Following the procedure for Example 59, starting from N-(5-(4- formylphenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and 4-methylρiperazine provided the title compound. ESIMS m/z = 427.3 (M+l).
Example 62 Preparation of N-(5-(4-piperidinomethyl-phenyl-lH-pyrroloF2,3-b]pyridin-3-yl)- nicotinamide
Following the procedure for Example 59, starting from N-(5-(4- formylphenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and piperidine provided the title compound. ES S m/z = 411.1 (M+l).
Example 63 Preparation of N-(5-(4-pyrrolidinomethyl-phenyl-lH-pyrroloF2,3-blpyridin-3-yl)- nicotinamide
Following the procedure for Example 59, starting from N-(5-(4- formylphenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and pyrrolidine provided the title compound. ESIMS m/z = 398.2 (M+l).
Example 64 Preparation of N-(5-(4-methylaminomethyl-phenyl- lH-pyrroloF2.3-b1pyridin-3-yl)- nicotinamide
Following the procedure for Example 59, starting from N-(5-(4- formylphenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and methylamine hydrochloride provided the title compound. ESIMS m/z = 358.2 (M+l).
Example 65 Preparation of N-(5-(4-diethanoIaminomethyl-phenyl-lH-pyrroloF2.3-b1pyridin-3- yl)-nicotinamide
Following the procedure for Example 59, starting from N-(5-(4- formylphenyl- lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and diethanolamine provided the title compound. ESIMS m/z = 432.4 (M+l).
Example 66 Preparation of N-(5-(4-(4-t-butoxycarbonyl)-piperazinomethyl-phenyl- 1 H- pyrrolo F2 , 3 -blpyridin-3 -yl)-nicotinamide
Following the procedure for Example 59, starting from N-(5-(4- f ormylphenyl- 1 H-pyrrolo [2,3 -b]pyridin-3 -yl)-nicotinamide and N-boc-piperazine provided the title compound. ESIMS m/z = 513.4 (M+l).
Example 67 Preparation of N-(5-(3-(4-t-butoxycarbonyl)-piperazinomethyl-phenyl-lH- ρyrroloF2,3-b1pyridin-3-yl)-nicotinamide
Following the procedure for Example 59, starting from N-(5-(3- formylphenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and N-boc-piperazine provided the title compound. ESIMS m/z = 513.6 (M+l).
Example 68 Preparation of N-(5-(3-dimethylaminomethyl-phenyl- lH-pyrroloF2,3-blpyridin-3- yl)-nicotinamide
Following the procedure for Example 59, starting from N-(5-(3- formylphenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and dimethylamine hydrochloride provided the title compound. ESIMS m/z = 372.2 (M+l).
Example 69 Preparation of N-(5-(3-(4-methylpiperazinomethyl)-phenyl-lH-pyrroloF2,3- bl p yridin-3 -yl)-nicotinamide
Following the procedure for Example 59, starting from N-(5-(3- formylphenyl- lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and 4-methylpiperazine provided the title compound. ESIMS m/z = 427.2 (M+l).
Example 70 Preparation ofN-(5-(3-morpholinomethyl-phenyl-lH-pyrroloF2,3-b1pyridin-3-yl)- nicotinamide
Following the procedure for Example 59, starting from N-(5-(3- formylphenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and morpholine provided the title compound. ESIMS m/z = 414.2 (M+l).
Example 71 Preparation of N-(5-(3-diethanolaminomethyl-phenyl-lH-pyrroloF2,3-blρyridin-3- yl)-nicotinamide
Following the procedure for Example 59, starting from N-(5-(3- formylphenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and diethanolamine provided the title compound. ESIMS m/z = 432.4 (M+l).
Example 72 Preparation of N-(5-(3-morpholinomethyI-phenyl-lH-pyrroloF2,3-blpyridin-3-yl)- butyramide
Following the procedure for Example 59, starting from N-(5-(3- formylphenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide and morpholine provided the title compound. ESIMS m/z = 379.2 (M+l).
Example 73 Preparation of N-(5-(3-(4-methylpiρerazinomethyl)-phenyl- lH-pyrroloF2,3- b1pyridin-3-yl)-butyramide
Following the procedure for Example 59, starting from N-(5-(3- formylphenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide and 4-methylpiperazine provided the title compound. ESIMS m/z = 392.4 (M+l).
Example 74 Preparation of N-(5-(4-moφholinomethyl-phenyl- lH-pyrroloF2,3-b1pyridin-3-yl)- butyr amide
Following the procedure for Example 59, starting from N-(5-(3- formylphenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide and morpholine provided the title compound. ESIMS m/z = 379.2 (M+l).
Example 75 Preparation of N-(5-(4-(4-methylpiρerazinomefhyl)-phenyl- lH-pyrroloF2,3- b1pyridin-3-yl)-butyr amide
Following the procedure for Example 59, starting from N-(5-(3- formylphenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide and 4-methylpiperazine provided the title compound. ESEVΪS m z = 392.4 (M+l).
Example 76 Preparation of thiophene-3-carboxylic acid (5-(4-hydoxy-phenyl)-lH-pyrroloF2,3- b1pyridin-3-yl)-amide
a) 5-(4-Ηydroxyphenyl)-3-nitro- lH-ρyrrolo[2,3-b]pyridine
Following the procedure for Example lb, starting from 5-bromo-3-nitro-lH- pyrrolo[2,3-b]pyridine and 4-hydroxybenzeneboronic acid provided the title compound. ESIMS m/z = 256.2 (M+l).
b) 3 - Amino-5 -(4-hydroxyphenyl)- 1 H-pyrrolo [2,3 -bjpyridine
Following the procedure for Example lc, starting from 5-(4-hydroxyphenyl)- 3-nitro-lH-pyrrolo[2,3-b]pyridine provided the title compound. ESIMS m/z = 226.4 (M+l).
c) Thiophene-3-carboxyIic acid (5-(4-hydroxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3- yl)-amide
Following the procedure for Example Id, starting from 3-amino-5-(4- hydroxyphenyl)-lH-pyrrolo[2,3-b]pyridine and thiophene-3-carbonyl chloride provided the title compound. ESIMS m z = 336.2 (M+l).
Example 77 Preparation of furan-2-carboxylic acid (5-(4-hydroxy-phenyl)-lH-pyrroloF2,3- blpyridin-3-yl)-amide
Following the procedure for Example Id, starting from 3-amino-5-(4- hydroxyphenyl)-lH-pyrrolo[2,3-b}pyridine and furan-2-carbonyl chloride provided the title compound. ESIMS m/z = 320.0 (M+l).
Example 78 Preparation of N-((5-(4-hydroxy-phenyl)- lH-pyrroloF2,3-blpyridin-3-yl)- nicotinamide
Following the procedure for Example Id, starting from 3-amino-5-(4- hydroxyphenyl)-lH-pyrrolo[2,3-b]pyridine and nicotonyl chloride hydrochloride provided the title compound. ESIMS m z = 331.2 (M+l).
Example 79 Preparation of pyrrole-2-carboxylic acid (5-(4-hydroxy-phenyl)-lH-pyrroloF2,3- blpyridin-3-yl)-amide
Following the procedure for Example Id, starting from 3-amino-5-(4- hydroxyphenyl)-lH-pyrrolo[2,3-b]pyridine and pyrrole-2-carbonyl chloride provided the title compound. ESIMS m/z = 319.2 (M+l).
Example 80 Preparation of 2-methyl-N-((5-(4-hydroxy-3-methoxy-phenyl)- lH-pyrroloF2,3- b]pyridin-3-yl)-benzamide a) 5-(4-Ηydroxy-3-methoxy-phenyl)-3-nitro-lH-pyrrolo[2,3-b]pyridine
Following the procedure for Example lb, starting from 5-bromo-3-nitro-lH- pyrrolo[2,3-b]pyridine and 4-hydroxy-3-methoxybenzeneboronic acid provided the title compound. ESIMS m z = 286.3 (M+l).
b) 3-amino-5-(4-Ηydroxy-3-methoxy-phenyl)-lH-pyrrolo[2,3-b]pyridine
Following the procedure for Example lc, starting 5-(4-hydroxy-3-methoxy- phenyl)-3-nitro-lH-pyrrolo[2,3-b]pyridine provided the title compound. ESIMS m/z = 256.2 (M+l).
c) 2-methyl-N-((5-(4-hydroxy-3-methoxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)- benzamide
Following the procedure for Example Id, starting from 3-amino-5-(4- hydroxy-3-methoxy-phenyl)- lH-pyrrolo[2,3-b]pyridine and 2-methylbenzoyl chloride provided the title compound. ESIMS m/z = 374.2 (M+l).
Example 81 Preparation of 2-chloro-N-((5-(4-hydroxy-3-methoxy-phenyl)- lH-pyrroloF2,3- blpyridin-3-yl -benzamide
Following the procedure for Example Id, starting from 3-amino-5-(4- hydroxy-3-methoxy-phenyl)-lH-pyrrolo[2,3-b]pyridine and 2-chlorobenzoyl chloride provided the title compound. ESIMS m/z = 394.2 (M+l).
Example 82 Preparation of N-((5-(4-hydroxy-3-methoxy-phenyl)-lH-pyrroloF2.3-b1ρyridin-3- yl)-2-methoxybenzamide
Following, the procedure for Example Id, starting from 3-amino-5-(4- hydroxy-3-methoxy-phenyl)- lH-pyrrolo[2,3-b]pyridine and 2-methoxybenzoyl chloride provided the title compound. ESIMS m/z = 390.2 (M+l).
Example 83 Preparation of pyrazine-2-carboxylic acid ((5-(4-hydroxy-3-methoxy-phenyl)-lH- pyrroloF2,3-b1pyridin-3-yl)-amide
Following the procedure for Example Id, starting from 3-amino-5-(4- hydroxy-3-methoxy-phenyl)- lH-pyrrolo[2,3-b]pyridine and pyrazine-2-carbonyl chloride provided the title compound. ESIMS m/z = 362.2 (M+l).
Example 84 Preparation of 2-hydroxy-N-((5-(4-hydroxy-3-methoxy-phenyl)- lH-pyrroloF2,3- b1pyridin-3-yl)-benzamide
Following the procedure for Example 50, starting from 3-amino-5-(4- hydroxy-3-methoxy-phenyl)- lH-pyrrolo[2,3-b]pyridine 2-hydroxybenzoic acid provided the title compound. ESIMS m/z = 376.2 (M+l).
Example 85 Preparation of pyrimidine-5-carboxylic acid-((5-(4-hydroxy-3-methoxy-phenyl)-lH- pyrrolor2,3-b1pyridm-3-yl)-amide
Following the procedure for Example 50, starting from 3-amino-5-(4- hydroxy-3-methoxy-phenyl)-lH-pyrrolo[2,3-b]pyridine pyrimidine-5-carboxylic acid provided the title compound. ESIMS m/z = 362.2 (M+l).
Example 86 Preparation of 5-bromo-N-((5-(4-hydroxy-3-methoxy-phenyl)- lH-pyrrolof 2.3- blpyridm-3-yl -nicotinamide
Following the procedure for Example 50, starting from 3-amino-5-(4- hydroxy-3-methoxy-phenyl)-lH-pyrrolo[2,3-b]pyridine 5-bromonicotinic acid provided the title compound. ESIMS m/z = 438.8 and 440.8.0 (M+l).
Example 87 Preparation of N-((5-(4-hydroxy-3-methoxy-phenyl - lH-pyrroloF2,3-b1pyridin-3- yl)-5-methyl-nicotinamide
Following the procedure for Example 50, starting from 3-amino-5-(4- hydroxy-3-methoxy-phenyl)- lH-pyrrolo[2,3-b]pyridine 5-methylnicotinic acid provided the title compound. ESIMS m/z = 375.2 (M+l).
Example 88 Preparation of N-((5-(benzothiophen-3-yl)- lH-pyrroloF2,3-blpyridin-3-yl)- nicotinamide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and benzothiophene-3-boronic acid provided the title compound. ESIMS m/z = 355.0 (M+l).
Example 89 Preparation of N-((5-(thiophen-2-yl)-lH-pyrroloF2,3-blpyridin-3-yl)-nicotinamide
Following the procedure for Example 17c, starting fromN-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and thiophene-2-boronic acid provided the title compound. ESIMS m/z = 321.1 (M+l).
Example 90 Preparation of N-((5-(4-methylpiperazinophenyI)- lH-pyrroIoF2,3-b]pyridin-3-yl)- nicotinamide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and 4-(4-mefhylpiperazino)benzene- boronic acid provided the title compound. ESIMS m/z = 413.4 (M+l).
Example 91 Preparation of N-((5-(3-biphenyl -lH-pyrroloF2,3-b]pyridin-3-yl)-nicotinamide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and 3-biphenyl-boronic acid provided the title compound. ESIMS m/z = 391.2 (M+l).
Example 92 Preparation of N-((5-(benzofuran-2-vD- lH-pyrroloF2,3-blpyridin-3-yl)-nicotinamide Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and benzofuran-2-yl-boronic acid provided the title compound. ESIMS m/z = 355.3 (M+l).
Example 93 Preparation of N-((5-(indol-5-vD- lH-pyrroloF2,3-b1pyridin-3-yl)-nicotinamide
Following the procedure for Example 17c, starting from N-(5-bromo-lH- pyrrolo[2,3-bjpyridin-3-yl)-nicotinamide and indole-5-boronic acid provided the title compound. ESIMS m/z = 354.3 (M+l).
Example 94
Figure imgf000043_0001
a) N-((5-(4-(Piperazin-l-yl-methyl)-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)- nicotinamide
Following the procedure for Example 59, starting from N-(5-(4- formylphenyl-lΗ-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide and piperazine provided the title compound. ESIMS m/z = 413.0 (M+l). b)
A solution of N-((5-(4-(piperazin- 1 -yl-methyl)-phenyl)- lH-pyrrolo[2,3- b]pyridin-3-yl)-nicotinamide in dimethylacetamide is treated with triethylamine and Rhodamine Green™ carboxylic acid, succinimidyl ester, hydrochloride (mixture of 5- and 6-isomers, from Molecular Probes, reagenet # R-6107). The solution is concentrated and purification by HPLC gives a mixture of:
Figure imgf000044_0001
With appropriate manipulation and protection of any chemical functionality, synthesis of the remaining compounds of Formula (I) is accomplished by methods analogous to those above.
In order to use a compound of Formula (I) or a pharmaceutically acceptable salt thereof for the treatment of humans and other mammals, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
The present ligands can be administered by different routes including intravenous, intraperitoneal, subcutaneous, intramuscular, oral, topical, transdermal, or transmucosal administration. For systemic administration, oral administration is preferred. For oral administration, for example, the compounds can be formulated into conventional oral dosage forms such as capsules, tablets and liquid preparations such as syrups, elixirs and concentrated drops.
Alternatively, injection (parenteral administration) may be used, e.g., intramuscular, intravenous, intraperitoneal, and subcutaneous. For injection, the compounds of the invention are formulated in liquid solutions, preferably, in physiologically compatible buffers or solutions, such as saline solution, Hank's solution, or Ringer's solution. In addition, the compounds may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms can also be produced.
Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, bile salts and fusidic acid derivatives. In addition, detergents may be used to facilitate permeation. Transmucosal administration, for example, may be through nasal sprays, rectal suppositories, or vaginal suppositories.
For topical administration, the compounds of the invention can be formulated into ointments, salves, gels, or creams, as is generally known in the art. The amounts of various compounds to be administered can be determined by standard procedures taking into account factors such as the compound IC50, EC50, the biological half-life of the compound, the age, size and weight of the patient, and the disease or disorder associated with the patient. The importance of these and other factors to be considered are known to those of ordinary skill in the art.
Amounts administered also depend on the routes of administration and the degree of oral bioavailability. For example, for compounds with low oral bioavailability, relatively higher doses will have to be administered.
Preferably the composition is in unit dosage form. For oral application, for example, a tablet, or capsule may be administered, for nasal application, a metered aerosol dose may be administered, for transdermal application, a topical formulation or patch may be administered and for transmucosal delivery, a buccal patch may be administered. In each case, dosing is such that the patient may administer a single dose.
Each dosage unit for oral administration contains suitably from 0.01 to 500 mg/Kg, and preferably from 0.1 to 50 mg/Kg, of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, calculated as the free base. The daily dosage for parenteral, nasal, oral inhalation, transmucosal or transdermal routes contains suitably from 0.01 mg to 100 mg/Kg, of a compound of Formula(I). A topical formulation contains suitably 0.01 to 5.0% of a compound of Formula (I).
The active ingredient may be administered from 1 to 6 times per day, preferably once, sufficient to exhibit the desired activity, as is readily apparent to one skilled in the art.
As used herein, "treatment" of a disease includes, but is not limited to prevention, retardation and prophylaxis of the disease. As used herein, "diseases" treatable using the present compounds include, but are not limited to leukemias, solid tumor cancers and metastases, lymphomas, soft tissue cancers, brain cancer, esophageal cancer, stomach cancer, pancreatic cancer, liver cancer, lung cancer, bladder cancer, bone cancer, prostate cancer, ovarian cancer, cervical cancer, uterine cancer, testicular cancer, kidney cancer, head cancer and neck cancer, chronic inflammatory proliferative diseases such as psoriasis and rheumatoid arthritis; proliferative cardiovascular diseases such as restenosis; prolifertive ocular disorders such as diabetic retinopathy; and benign hyperproliferative diseases such as hemangiomas.
Composition of Formula (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as syrups, tablets, capsules and lozenges. A syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with a flavoring or coloring agent. Where the composition is in the form of a tablet, any pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include magnesium stearate, terra alba, talc, gelatin, acacia, stearic acid, starch, lactose and sucrose. Where the composition is in the form of a capsule, any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatin capsule shell. Where the composition is in the form of a soft gelatin shell capsule any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates or oils, and are incorporated in a soft gelatin capsule shell.
Typical parenteral compositions consist of a solution or suspension of a compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a parenterally acceptable oil, for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil or sesame oil.
Typical compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or trichlorofluoromefhane.
A typical suppository formulation comprises a compound of Formula (I) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent, for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or.their synthetic analogs.
Typical dermal and transdermal formulations comprise a conventional aqueous or non-aqueous vehicle, for example a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.
Preferably the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer a single dose.
No unacceptable toxological effects are expected when compounds of the present invention are administered in accordance with the present invention.
The biological activity of the compounds of Formula (I) are demonstrated by the tests indicated hereinbelow. Chkl Methods:
Streptavidin coated SPA beads, ATP and 33P-ATP were obtained from Amersham Pharmacia Biotech, Biotin labeled peptide KVSRSGLYRSPSMPENLNRK(Biotin-xx)NH2 was obtained from Affiniti Research Products Ltd, assay buffer reagents were obtained from Sigma-Aldrich Co.Ltd. fff84 well assay plates were obtained from Corning Inc. Assay buffer: 50 mM HEPES, 50 mM KC1, 5% Glycerol, 1 mM EGTA, 0.001% Tween-20; enzyme/peptide mix: 25 nM Chkl, 2.5μM biotin peptide, 7.5 mM 2- mercaptoethanol in assay buffer; ATP mix: 20μM ATP at 650kBq/mL, 5mM MgCl2 in assay buffer. Inhibitors of decreasing concentration, from lOuM were incubated at room temperature for 1 hour together with 5μL enzyme/peptide mix and 5μL ATP mix. The reaction was stopped with 5μL of 0.5M EDTA followed by a further addition of 65uL of 0.2mg/mL SPA beads. Plates were spun at 2500 rpm for 10 minutes and the amount of 33P incorporated onto the peptide was quantified by a Wallac Trilux scintillation counter at a read time of 1 minute per well. IC50's were fitted to the data using SDM Explorer version 2.5 software (©GlaxoSmthKline Pic).
Compounds capable of inhibiting Chkl kinase can be identified with in vitro assays and cellular assays as described below. Variations of these assays would be obvious to those skilled in the art. Expression of GST-Chkl:
A GST-Chkl expression construct was constructed which has the glutathione-S-transferase gene fused to the amino terminus of Chkl kinase via a linker containing a thrombin cleavage site. This construct was cloned into the Baculovirus expression vector, pFASTBAC, and this was used to make the viral stock for the subsequent infection. Spodoptera frugiperda cells (Sf9) were infected with the virus expressing the GST-Chkl and the cells were grown for 3 days, then harvested and frozen down. Purification of GST-Chkl:
The GST-Chkl protein was purified as follows: An Sf9 cell pellet expressing GST-Chkl was resuspended on ice in lysis buffer (50mM Tris-Cl, pH 7.5, 250mM NaCl2, ImM dithiothreitol (DTT), 0.1%Brij, 5% (v/v) protease inhibitor cocktail, lmM sodium orthovanadate), cells were lysed by sonication and centrifuged at 100,000xg for 30min The supernatant was added to Glutathione Sepharose 4B, beads, equilibrated in wash buffer (20mM Tris-Cl, pH 7.0, lOmM MgCl2, lOOmM NaCl2, ImM DTT, 0.5%(v/v) protease inhibitor cocktail, ImM sodium orthovanadate). The mixture was rocked for 30min The resin with the bound GST- Chkl was spun down at 500xg for 5min and washed with 14mls of wash buffer. The beads were spun as above and resuspended in another 14mls of wash buffer. The suspension was transferred into a column and allowed to pack, then the wash buffer was allowed to flow through by gravity. The GST-Chkl was eluted from the column with lOmM Glutathione in 50rnM Tris-Cl, pH 8.0 in 500ul fractions. Protein concentrations were determined on the fractions using Bio-Rad's Protein assay kit as per instructions. Fractions containing the GST-Chkl were pooled and diluted to a concentration of ~0.5mg/ml and dialyzed for 4 hours at 4^C in dialysis buffer (20mM HEPES, pH 7.0, ImM Manganese Acetate, lOOmM NaCl2, 0.05% Brij-35, 10% glycerol, ImM DTT, 0.2% (v/v) protease inhibitor cocktail, ImM sodium orthovanadate). The protein was aliquoted and stored at -80^. Cell Cycle Studies:
Drug studies considering cellular effects were performed in the Hela S3 adherent cell line. Cells were plated at a concentration sufficiently low such that 24 hours later they were at 10-20% confluence (typically 2 10^ cells/15cm e3). Cells were then synchronized in S phase by a repeated thymidine block. Briefly, cells were treated with 2mM thymidine for 18hours, released for 8 hours by 3 washes, and then treated again with thymidine. Following the second release from thymidine, 95% of cells were in S phase. Synchronized cells were then returned to complete media containing a DNA-damaging drug such as 50nM topotecan (a dosage we have found to be sufficient to arrest cells in early G2 phase without inducing apoptosis) alone and in combination with test compounds for up to 18 hours. Cell cycle profiles were then performed cytometrically using a procedure for propidium iodide staining of nuclei. (Vindelov et al, Cytometry Vol.3, No.5, 1983, 323-327) CHK1 inhibitors would be expected to reverse the G2 arrest caused by the DNA damaging agent. Typical concentration ranges for such activity would be 0.001 to 10 uM. Proliferation/Apoptosis Studies:
Proliferation studies were performed in a variety of adherent and non- adherent cell lines including Hela S3, HT29, and Jurkat. The proliferation assay utilized a colorimetric change resulting from reduction of the tetrazolium reagent XTT into a formazan product by metabolically active cells
(Scudiero et al. Cancer Research, 48, 1981, 4827-4833) Cells were seeded in lOOul in 96 well plates to roughly 10% confluence (cell concentration varied with cell lines) and grown for 24 hours. Compounds were then added with or without sufficient vehicle- containing media to raise the cells to a 200ul final volume containing chemical reagents in 0.2% DMSO. Cells received multiple concentrations of DNA-damaging anti-proliferative drugs such as topotecan, test compounds, and combination treatment at 37°C 5% CO2. 72 hours later, 50 uls of an XTT/ phenazine methosulfate mixture were added to each well and cells were left to incubate for 90mins. Plate was read at 450nm, and anti-proliferative effects were compared relative to vehicle treated cells. CHK1 inhibitors are expected to enhance the cytotoxicity of DNA-damaging chemotherapeutic drugs. Typical concentration ranges for such activity would be 0.001 to 10 uM. Other assays for cellular proliferation or cytotoxicity could also be used with test compounds, and these assays are known to those skilled in the art.
Formulations for pharmaceutical use incorporating compounds of the present invention can be prepared in various forms and with numerous excipients. Examples of such formulations are given below:
All publications, including but not limited to patents and patent applications cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference as though fully set forth.

Claims

What is claimed is:
1. A compound according to Formula (I) hereinbelow:
Figure imgf000051_0001
(I) wherein:
R1 is aryl or heteroaryl, wherein aryl or heteroaryl may optionally be substituted by one or more of group A and on any position with the exception that R1 is not 3,4- dichlorophenyl,
A is selected from the group consisting of CM0 alkyl, CM0 alkanoyl, C2.10 alkenyl, C2.10 alkynyl, C3.10 cycloalkyl, C06 alkylaryl, C06 alkylheterocyclyl, C06 alkylheteroaryl,
C(=NH)R3, COR3, CONR3R4, CON(O)R3R4, CO2R3, C(O)SR3, C(S)R3, cyano, trifluoromethyl, NR3R4, N(O)R3R4, NR3COR4, NR3CONR4R5, NR3CON(O)R4R5,
NR3CO2R3, NR3C(O)SR3, NR3SO2R3, nitro, OR3, OCF3, aryloxy, heteroaryloxy, SR3,
S(O)R3, S(O)2R3, SCF3, S(O)CF3, S(O)2CF3, SO2NR3R4, SO3R3, PO3R3R4, and halo, wherein CM0 alkyl, Cj_10 alkanoyl, C2_10 alkenyl, C2 10 alkynyl, C3 10 cycloalkyl, C0_5 alkylaryl, C05 alkylheterocyclyl, C05 alkylheteroaryl, (CH2)0.5heteroaryl, aryloxy, and heteroaryloxy may be optionally substituted by one or more of group B and on any position;
B is selected from the group consisting of Cul0 alkyl, C,.10 alkanoyl, C2 10 alkenyl, C2_l0 alkynyl, C3.10 cycloalkyl, C05 alkylaryl, C05 alkylheterocyclyl, C0_6 alkylheteroaryl, C(=NH)R3, COR3, CONR3R4, CON(O)R3R4, CO2R3, C(O)SR3, C(S)R3, cyano, trifluoromethyl, NR3R4, N(O)R3R4, NR3COR4, NR3CONR4R5, NR3CON(O)R4R5, NR3CO2R3, NR3C(O)SR3, NR3SO2R3, nitro, OR3, OCF3, aryloxy, heteroaryloxy, SR3, S(O)R3, S(O)2R3, SCF3, S(O)CF3, S(O)2CF3, SO2NR3R4, SO3R3, PO3R3R4, and halo, wherein C,.10 alkyl, C,.,,, alkanoyl, C2.10 alkenyl, C2.10 alkynyl, C3.10 cycloalkyl, C0.6 alkylaryl, C06 alkylheterocyclyl, C06 alkylheteroaryl, (CH2)0.6heteroaryl, aryloxy, and heteroaryloxy may be optionally substituted by one or more of group C and on any position;
R3, R4, and R5 are independently selected from the group consisting of hydrogen, C 0 alkyl, C,.10 alkanoyl, C2.10 alkenyl, C2.10 alkynyl, C3.10 cycloalkyl, C0.6 alkylaryl, C0.6 alkylheterocyclyl, and C0_6 alkylheteroaryl; or R3 and R4 taken together with the nitrogen to which they are attached form a ring having 3 to 7 carbon atoms optionally containing 1, 2, or 3 heteroatoms selected from nitrogen, sulfur, oxygen, or nitrogen, substituted with hydrogen, C,_6 alkyl or (CH2)0.3aryl, wherein any of the foregoing may be optionally substituted by one or more of group C and on any position;
C is selected from the group consisting of C 0 alkyl, CM0 alkanoyl, C2.10 alkenyl, C2 10 alkynyl, C3.10 cycloalkyl, C0.6 alkylaryl, C0_6 alkylheterocyclyl, C0.6 alkylheteroaryl, C(=NH)R6, COR6, CONR6R7, CON(O)R6R7, CO2R6, C(O)SR6, C(S)R6, cyano, trifluoromethyl, NR6R7, N(O)R6R7, NR6COR6, NR6CONR R8, NR6CON(O)R7R8, NR6CO2Rδ, NR6C(O)SR6, NR6SO2R6, nitro, OR6, OCF3, aryloxy, heteroaryloxy, SR6, S(O)R6, S(O)2R6, SCF3, S(O)CF3, S(O)2CF3, SO2NR6R7, SO3R6, PO3R R7, and halo, wherein C,.8 alkyl, C,_8 alkanoyl, C2.8 alkenyl, C2_8 alkynyl, C3 g cycloalkyl, C0_6 alkylaryl, C06 alkylheterocyclyl, C06 alkylheteroaryl may be optionally substituted by one or more of C(=NH)R6, COR6, CONR6R7, CON(O)R6R7, CO2R6, C(O)SR6, C(S)R6, cyano, trifluoromethyl, NR6R7, N(O)R6R7, NR6COR6, NR6CONR7R8, NR6CON(O)R7R8, NR6CONR6R7R8Y, NR6CO2R6, NR6C(O)SR6, NR6SO2R6, nitro, OR6, aryloxy, heteroaryloxy, SR6, S(O)R6, S(O)2R6, SO2NR6R7, SO3R6, PO3R6R7, or halo, and on any position;
R6, R7, and R8 are independently selected from the group consisting of hydrogen, C I0 alkyl, C,.10 alkanoyl, C2 10 alkenyl, C2 10 alkynyl, C3.10 cycloalkyl, C0.6 alkylaryl, C06 alkylheterocyclyl, and C0.6 alkylheteroaryl; or R7 and R8 taken together with the nitrogen to which they are attached form a ring having 3 to 7 carbon atoms optionally containing 1 , 2, or 3 heteroatoms selected from nitrogen, sulfur, oxygen, or nitrogen, substituted with hydrogen, CU6 alkyl or (CH2)03aryl;
R2 is selected from the group consisting of Cι_8 alkyl, C2.8 alkenyl, C3.6 cycloalkyl, OR9, NR10Rn, phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazolinyl, thiazinyl, pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl and thiadiazolyl, wherein alkyl and alkenyl and cycloalkyl may optionally be substituted with one of more of group D and at any position and wherein phenyl may be optionally subtituted at positions 3-, 4-, and 5- with one to three of group E and wherein pyridyl, pyridazinyl, pyrimidinyl, pyrazolinyl, thiazinyl, pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl and thiadiazolyl may optionally be substituted by one or more of group F and at any position, with the preferred substitution being n- propyl or pyridyl or pyrazolinyl, with the more preferred substitution being 3-pyridyl R9 is hydrogen or _6 alkyl, wherein any of the foregoing groups are optionally substituted with one or more of group D and at any position, with the exception that R9 is not tert-butyl;
R10 is selected from the group consisting of hydrogen, methyl and ethyl; RH is selected from the group consisting of hydrogen, C1 6 alkyl, C2 8 alkenyl and C3.6 cycloalkyl, wherein any of the foregoing groups are optionally substituted with one or more of group D and at any position;
R10 and R11 taken together with the nitrogen to which they are attached may form a ring having 3 to 7 carbon atoms optionally containing 1, 2, or 3 heteroatoms selected from nitrogen, sulfur, oxygen, or nitrogen, substituted with hydrogen or C,.6 alkyl; D is selected from the group consisting of C,_6 alkyl, C2.8 alkenyl, C3.6 cycloalkyl, OR12, OC(O)NR12R13, NR1 SO2R12R13, NR14C(O)OR12, NR14C(O)NR12R13, halo, cyano, trifluoromethyl, SR12, S(O)R12, SO2R12, SO3R12, SO2NR12R13, C(O)SR12, CONR,2R13 and PO3R12;
R12, R13, R1 are independently selected from the group consisting of hydrogen, C1 3 alkyl, C2.3 alkanoyl, C2.3 alkenyl, C,_3 alkynyl, and C3.5 cycloalkyl; or R12 and R13 taken together with the nitrogen to which they are attached form a ring having 3 to 7 carbon atoms optionally containing 1, 2, or 3 heteroatoms selected from nitrogen, sulfur, oxygen, or nitrogen, substituted with hydrogen or C,_3 alkyl;
E is selected from the group consisting of C,.4 alkyl, OR15 and NR15R16, with the exception that R2 is not 3,4-dimethoxyphenyl or 3 -methoxy phenyl,
F is selected from the group consisting of C 6 alkyl, C2.8 alkenyl, C3.6 cycloalkyl,
OR12, OC(O)NR12R13, NR12R13, NR14SO2R12R13, NR14C(O)OR12, NRI4C(O)NR1 R13, halo, cyano, trifluoromethyl, SR12, S(O)R12, SO2R12, SO3R12, SO2NR12R13, C(O)SR12,
CONR12R13 and PO3R12;
R15 and R16 are independently selected from the group consisting of hydrogen, CI 3 alkyl, C, 3 alkanoyl, C2.3 alkenyl, C2.3 alkynyl, and C3 5 cycloalkyl; or R15 and R16 taken together with the nitrogen to which they are attached form a ring having 3 to 7 carbon atoms optionally containing 1, 2, or 3 heteroatoms selected from nitrogen, sulfur, oxygen, or nitrogen, substituted with hydrogen or C1 3 alkyl.
2. A compound according to claim 1 wherein any substitution at Rl is 3-,4- or 5-alkoxy- or hydroxy- or amino- or hydroxymethyl- or aminomethyl- or acetamido- or aminosulfamoyl- or dimethylamino- phenyl including di- and tri-substitution or 3- thienyl.
3. A compound according to claim 2 wherein any substitution at Rl is 4- hydroxy-3-methoxyphenyl or 3-acetamidophenyl or 3,4-dimethoxyphenyl or 4- aminophenyl or 4-aminomethylphenyl;
4. A compound according to claim 1 wherein the compound is selected from the group consisting of:
3-dimethylamino-N-(5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-benzamide; 4-methoxy-N-(5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-benzamide; l-ethyl-3-(5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-urea; benzo[l ,3]dioxole-5-carboxylic acid (5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)- amide;
N-(5-(3-carboxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide; N-(5-(4-chloro-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-benzamide;
N-(5-(4-carboxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
4-acetylamino-N-(5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-benzamide;
N-(5-(3-chloro-phenyl)-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-isonicotinamide; acetic acid (5-phenyl-lH-pyrrolo[2,3-b}pyridin-3-ylcarbamoyl)-methyl ester;
6-(2-(pyrrolidin-l-yl)ethyl-N-(5-phenyl-lΗ-pyrrolo[2,3-b]pyridin-3-yl)- nicotinamide;
3-hydroxy-N-(5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-benzamide;
N-(5-(4-cyano-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-(4-acetyl-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyr amide;
N-(5-(pyridin-3-yl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-(3-fluoro-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-(3-methyl-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyr amide;
(5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-carbamic acid ethyl ester;
N-(5-(4-methylsulfonyl-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
2-methoxy-N-(5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-acetamide;
( 1 H-pyrrolo [2,3 -b]pyridin-3 -yl)-nicotinamide ;
N-(5-(3-hydroxymethyl-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide; pyridine-2-carboxylic acid (5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-amide;
N-(5-(pyridin-4-yl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-isobutyramide;
N-(5-(4-dimethylamino-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-(4-hydroxymethyl-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
6-methyl-N-(5-phenyl-lΗ-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide; thiophene-2-carboxylic acid (5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-amide;
N-(5-(4-sulfamoylphenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-(3-aminophenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-(4-acetamido-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide; N-(5-(4-hydroxy -phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(3-methoxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide; furan-2-carboxylic acid (5-(4-hydroxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)- amide; furan-3-carboxylic acid (5-(4-hydroxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)- amide; thiophene-3 -carboxylic acid (5-(4-hydroxy-phenyl)- lH-pyrrolo[2,3-b]pyridin-3-yl)- amide; pyrrole-2-carboxylic acid (5-(4-hydroxy-phenyl)- lH-pyrrolo[2,3-b]pyridin-3-yl)- amide
N-(5-(4-methyl-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-(4-(morpholin-l-yl)-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-(4-(4-methyl-piperazin-l-yl)-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)- butyramide;
5-methyl-N-(5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
5-bromo-N-(5-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
2,6-dimethoxy-N-(5-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(4-aminomethylphenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(3-formylphenyl-lΗ-pyrrolo[2,3-b]pyridin-3-yl)-butyr amide;
N-(5-(4-formylphenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-(3-formylphenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotmamide;
N-(5-(4-formylphenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(4-(4-t-butoxycarbonyl)-piperazinomethyl-phenyl-lH-pyrrolo[2,3-b]pyridin-3- yl)-nicotinamide;
N-(5-(4-(4-t-butoxycarbonyl)-piperazinomethyl-phenyl-lH-pyrrolo[2,3-b]pyridin-3- yl)-nicotinamide;
N-(5-(3-(4-t-butoxycarbonyl)-methyl-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)- nicotinamide;
N-(5-(3-morpholinomethyl-phenyl-lH-pyrrolo[2,3-b]ρyridin-3-yl)-butyramide;
N-(5-(3-(4-methylpiperazinomethyl)-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)- butyr amide; N-(5-(4-morpholinomethyl-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyr amide;
N-(5-(4-(4-methylpiperazinomethyl)-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)- butyr amide;
2-methyl-N-((5-(4-hydroxy-3-methoxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)- benzamide;
2-chloro-N-((5-(4-hydroxy-3-methoxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)- benz amide;
N-((5-(4-hydroxy-3-methoxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-2- methoxybenz amide;
2-hydroxy-N-((5-(4-hydroxy-3-methoxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)- benzamide; pyrimidine-5-carboxylic acid-((5-(4-hydroxy-3-methoxy-phenyl)-lH-pyrrolo[2,3- b]pyridin-3-yl)-amide;
N-((5-(benzothiophen-3-yl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-((5-(thiophen-2-yl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-((5-(3 -biphenyl)- lH-pyrrolo [2,3 -b]pyridin-3 -yl)-nicotinamide ;
N-((5-(benzofuran-2-yl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-((5-(indol-5-yl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide; pyrazine-2-carboxylic acid ((5-(4-hydroxy-3-methoxy-phenyl)- lH-pyrrolo[2,3- b]pyridin-3-yl)-amide; and
N-(5-(4-aminomethylphenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide.
5. A compound according to claim 4 selected from the group consisting of :
N-(5-(thiophen-3-yl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-(4-hydroxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-(3,4-dimethoxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-(3-sulfamoylphenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-(3-acetamide-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-(naphthalen-2-yl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
4-methyl-N-(5-phenyl-lΗ-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide; pyrazine-2-carboxylic acid (5-phenyl- lH-pyrrolo[2,3-b]pyridin-3-yl)-amide; N-(5-(4-aminomethylphenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-butyramide;
N-(5-phenyl-lH-pyπOlo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(4-methoxyphenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(4-dimethylamino-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(3,4-(methylenedioxy)-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(3,5-dimethyl-4-hydroxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)- nicotinamide;
N-(5-(4-hydroxymethyl-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(thiophen-3-yl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(4-aminophenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(3,4-dimethoxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(3-acetamido-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(4-hydroxy-3-methoxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(4-(dimethylaminomethyl)-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)- nicotinamide;
N-(5-(3,5-dimethyl-4-hydroxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)- nicotinamide;
N-(5-(4-hydroxymethyl-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(4-diethanolaminomethyl-phenyl-lΗ-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(3-dimethylaminomethyl-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(3-(4-methylpiperazinomethyl)-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)- nicotinamide;
N-(5-(3-morpholinomethyl-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(3-diethanolaminomethyl-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(4-(morpholin-l-yl)-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide; and
N-(5-(4-(4-methyl-piperazin-l-yl)-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)- nicotinamide.
6. A compound according to claim 5 selected from the group consisting of :
N-(5-(4-morpholinomethyl-phenyl-lΗ-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide; N-(5-(4-piperidinomethyl-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide; N-(5-(4-pyrrolidmomethyl-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(4-methylaminomethyl-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(thiophen-3-yl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(4-aminophenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(3,4-dimethoxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(3-acetamido-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(4-hydroxy-3-methoxy-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide;
N-(5-(4-(dimethylaminomethyl)-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)- nicotinamide;
N-(5-(4-(morpholin-l-yl)-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)-nicotinamide; and
N-(5-(4-(4-methyl-piperazin-l-yl)-phenyl)-lH-pyrrolo[2,3-b]pyridin-3-yl)- nicotinamide. I
7. A method of inhibiting angiogenesis or damage response kinase activity which comprises administering to a subject in need thereof, an effective amount of a compound according to claim 1.
8. A method according to claim 7 wherein the kinase being inhibited in chk-1 kinase.
9. A method according to claim 7 wherein the disease or disorder being treated is selected from the group consisting of leukemia, solid tumor cancer, metastases, lymphomas, soft tissue cancers, brain cancer, esophageal cancer, stomach cancer, pancreatic cancer, liver cancer, lung cancer, bladder cancer, bone cancer, prostate cancer, ovarian cancer, cervical cancer, uterine cancer, testicular cancer, kidney cancer, head cancer and neck cancer, chronic inflammatory proliferative diseases, proliferative cardiovascular diseases, proliferative ocular disorders and benign hyperproliferative diseases.
10. A compound with the formula below:
Figure imgf000060_0001
PCT/US2002/031842 2001-10-04 2002-10-04 Chk1 kinase inhibitors WO2003028724A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32697401P 2001-10-04 2001-10-04
US60/326,974 2001-10-04

Publications (1)

Publication Number Publication Date
WO2003028724A1 true WO2003028724A1 (en) 2003-04-10

Family

ID=23274578

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/031842 WO2003028724A1 (en) 2001-10-04 2002-10-04 Chk1 kinase inhibitors

Country Status (1)

Country Link
WO (1) WO2003028724A1 (en)

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004093873A1 (en) * 2003-04-17 2004-11-04 Janssen Pharmaceutica, N.V. 2-phenyl-benzimidazol and 2-phenyl-imidazo-`4,5!-pyridine derivatives as checkpoint kinase cds1 (chk2) inhibitors for the treatment of cancer
WO2004078756A3 (en) * 2003-03-06 2005-03-24 Eisai London Res Lab Ltd Jnk inhibitors
WO2006015123A1 (en) * 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
WO2006040049A1 (en) * 2004-10-14 2006-04-20 F. Hoffmann-La Roche Ag Novel azaindole thiazolinones as anti-cancer agents
WO2005103050A3 (en) * 2004-04-02 2006-10-05 Vertex Pharma Azaindoles useful as inhibitors of rock and other protein kinases
FR2884821A1 (en) * 2005-04-26 2006-10-27 Aventis Pharma Sa New pyrrolo pyridine compounds are kinase inhibitors useful as an inhibiting agent for kinase-catalyzed reaction and for the manufacture of a drug to treat cancer
EP1740100A1 (en) * 2004-04-13 2007-01-10 Biosearch Technologies, Inc. Xanthene dyes
WO2007106236A2 (en) * 2006-02-27 2007-09-20 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7452993B2 (en) 2004-07-27 2008-11-18 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7534800B2 (en) 2002-03-28 2009-05-19 Eisai R & D Development Co., Ltd. 7-azaindoles as inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders
WO2009089352A1 (en) 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
US7612086B2 (en) 2003-05-16 2009-11-03 Eisai R & D Management Co. Ltd. JNK inhibitors
WO2009140320A1 (en) * 2008-05-13 2009-11-19 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US20090312355A1 (en) * 2006-08-03 2009-12-17 Trustees Of Tufts College Non-Flushing Niacin Analogues, and Methods of Use Thereof
US7645769B2 (en) 2005-08-05 2010-01-12 Eisai R & D Management Co., Ltd. Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation
US7652137B2 (en) 2003-03-06 2010-01-26 Eisai R & D Management Co., Ltd. Synthesis of 5 substituted 7-azaindoles and 7-azaindolines
WO2010016490A1 (en) 2008-08-05 2010-02-11 第一三共株式会社 Imidazopyridin-2-on derivative
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7846941B2 (en) 2005-05-17 2010-12-07 Plexxikon, Inc. Compounds modulating c-kit and c-fms activity and uses therefor
US7863288B2 (en) 2005-06-22 2011-01-04 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
US7893075B2 (en) 2006-11-22 2011-02-22 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US7947708B2 (en) 2004-06-17 2011-05-24 Plexxikon, Inc. Compounds modulating C-kit activity
EP2325184A1 (en) * 2004-06-30 2011-05-25 Vertex Pharmceuticals Incorporated Azaindoles useful as inhibitors of protein kinases
EP2330105A1 (en) 2005-03-29 2011-06-08 ICOS Corporation Heteroaryl urea derivatives useful for inhibiting CHK1
US8067434B2 (en) 2003-12-19 2011-11-29 Plexxikon Inc. Compounds and methods for development of Ret modulators
WO2012074754A1 (en) 2010-11-16 2012-06-07 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
JP2012523435A (en) * 2009-04-11 2012-10-04 アレイ バイオファーマ、インコーポレイテッド Checkpoint kinase 1 inhibitor for enhancing DNA damaging factors
US8372842B2 (en) 2008-01-09 2013-02-12 Array Biopharma Inc. Pyrazolopyridines as kinase inhibitors
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
US8865735B2 (en) 2011-02-21 2014-10-21 Hoffman-La Roche Inc. Solid forms of a pharmaceutically active substance
JP2015505555A (en) * 2012-01-30 2015-02-23 ヴァーナリス （アールアンドディー） リミテッドＶｅｒｎａｌｉｓ （Ｒ＆Ｄ） Ｌｉｍｉｔｅｄ 1H-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitors
US9096593B2 (en) 2009-11-06 2015-08-04 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US9228225B2 (en) 2004-02-03 2016-01-05 Biosearch Technologies, Inc. Xanthene dyes
AU2013218743B2 (en) * 2008-05-13 2016-04-28 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
US9447089B2 (en) 2009-04-03 2016-09-20 Plexxikon Inc. Compositions and uses thereof
US9469640B2 (en) 2007-07-17 2016-10-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
RU2672725C2 (en) * 2013-08-22 2018-11-19 Дженентек, Инк. Method of preparing compound
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN109942574A (en) * 2019-01-11 2019-06-28 成都阿奇生物医药科技有限公司 Its surprise is for Buddhist nun and its preparation method and application
WO2020150417A2 (en) 2019-01-17 2020-07-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2022015979A1 (en) 2020-07-15 2022-01-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2022015977A1 (en) * 2020-07-15 2022-01-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2022150543A1 (en) 2021-01-08 2022-07-14 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2022237922A1 (en) * 2021-05-10 2022-11-17 Fakultni Nemocnice Hradec Kralove Antitumor compounds based on nitrogen heterocycles and use thereof as medicaments
US11618749B2 (en) 2018-07-03 2023-04-04 Ifm Due, Inc. Compounds and compositions for treating conditions associated with STING activity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681959A (en) * 1995-02-21 1997-10-28 Merck, Sharp & Dohme Ltd. Chemical synthesis of azaindoles
US5750536A (en) * 1993-08-05 1998-05-12 Dompe ' Spa Tropyl 7-azaindol-3-ylcarboxyamides as antitussive agent
DE10053122A1 (en) * 1999-11-20 2001-05-23 Wella Ag Synthesis of indole and pyrrolo(2,3-b)pyridine compounds, used for coloring keratinous fibers, e.g. human hair, involves conversion of tryptophan derivative with tryptophanase enzyme in presence of pyridoxal phosphate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750536A (en) * 1993-08-05 1998-05-12 Dompe ' Spa Tropyl 7-azaindol-3-ylcarboxyamides as antitussive agent
US5681959A (en) * 1995-02-21 1997-10-28 Merck, Sharp & Dohme Ltd. Chemical synthesis of azaindoles
DE10053122A1 (en) * 1999-11-20 2001-05-23 Wella Ag Synthesis of indole and pyrrolo(2,3-b)pyridine compounds, used for coloring keratinous fibers, e.g. human hair, involves conversion of tryptophan derivative with tryptophanase enzyme in presence of pyridoxal phosphate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JACKSON ET AL.: "An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage", CANCER RESEARCH, vol. 60, no. 3, 1 February 2000 (2000-02-01), pages 566 - 572, XP002959445 *

Cited By (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534800B2 (en) 2002-03-28 2009-05-19 Eisai R & D Development Co., Ltd. 7-azaindoles as inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders
WO2004078756A3 (en) * 2003-03-06 2005-03-24 Eisai London Res Lab Ltd Jnk inhibitors
US7432375B2 (en) 2003-03-06 2008-10-07 Eisai R & D Management Co., Ltd. JNK inhibitors
US7652137B2 (en) 2003-03-06 2010-01-26 Eisai R & D Management Co., Ltd. Synthesis of 5 substituted 7-azaindoles and 7-azaindolines
US7687639B2 (en) 2003-04-17 2010-03-30 Janssen Pharmaceutica N.V. Substituted benzimidazoles and imidazo-[4,5]-pyridines
WO2004093873A1 (en) * 2003-04-17 2004-11-04 Janssen Pharmaceutica, N.V. 2-phenyl-benzimidazol and 2-phenyl-imidazo-`4,5!-pyridine derivatives as checkpoint kinase cds1 (chk2) inhibitors for the treatment of cancer
JP2006523712A (en) * 2003-04-17 2006-10-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 2-Phenyl-benzimidazole and 2-phenyl-imidazo-'4,5 as checkpoint kinase CDS1 (CHK2) inhibitors for the treatment of cancer! -Pyridine derivatives
US7132440B2 (en) 2003-04-17 2006-11-07 Janssen Pharmaceutica, N.V. Substituted benzimidazoles and imidazo-[4,5]-pyridines
JP4726235B2 (en) * 2003-04-17 2011-07-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 2-Phenyl-benzimidazole and 2-phenyl-imidazo-'4,5 as checkpoint kinase CDS1 (CHK2) inhibitors for the treatment of cancer! -Pyridine derivatives
US7612086B2 (en) 2003-05-16 2009-11-03 Eisai R & D Management Co. Ltd. JNK inhibitors
US8067434B2 (en) 2003-12-19 2011-11-29 Plexxikon Inc. Compounds and methods for development of Ret modulators
US9228225B2 (en) 2004-02-03 2016-01-05 Biosearch Technologies, Inc. Xanthene dyes
WO2005103050A3 (en) * 2004-04-02 2006-10-05 Vertex Pharma Azaindoles useful as inhibitors of rock and other protein kinases
US7514448B2 (en) 2004-04-02 2009-04-07 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
EP1740100A1 (en) * 2004-04-13 2007-01-10 Biosearch Technologies, Inc. Xanthene dyes
EP1740100A4 (en) * 2004-04-13 2009-09-16 Biosearch Technologies Inc Xanthene dyes
US7947708B2 (en) 2004-06-17 2011-05-24 Plexxikon, Inc. Compounds modulating C-kit activity
EP2325184A1 (en) * 2004-06-30 2011-05-25 Vertex Pharmceuticals Incorporated Azaindoles useful as inhibitors of protein kinases
AU2005260689B2 (en) * 2004-06-30 2012-05-10 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of protein kinases
US7906648B2 (en) 2004-07-27 2011-03-15 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7829558B2 (en) 2004-07-27 2010-11-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
JP2008508303A (en) * 2004-07-27 2008-03-21 エスジーエックス ファーマシューティカルズ、インコーポレイテッド Pyrrolo-pyridine kinase modulator
WO2006015123A1 (en) * 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7582637B2 (en) 2004-07-27 2009-09-01 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7601839B2 (en) 2004-07-27 2009-10-13 Sgx Pharmaceuticals Inc. Pyrrolo-pyridine kinase modulators
US7361763B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US8268994B2 (en) 2004-07-27 2012-09-18 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7452993B2 (en) 2004-07-27 2008-11-18 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7247727B2 (en) 2004-10-14 2007-07-24 Hoffmann-La Roche Inc. Azaindole thiazolinones
JP2008516903A (en) * 2004-10-14 2008-05-22 エフ．ホフマン−ラ ロシュ アーゲー Novel azaindole thiazolinones as anticancer agents
WO2006040049A1 (en) * 2004-10-14 2006-04-20 F. Hoffmann-La Roche Ag Novel azaindole thiazolinones as anti-cancer agents
AU2005293831B2 (en) * 2004-10-14 2011-01-06 F. Hoffmann-La Roche Ag Novel Azaindole thiazolinones as anti-cancer agents
EP2330105A1 (en) 2005-03-29 2011-06-08 ICOS Corporation Heteroaryl urea derivatives useful for inhibiting CHK1
WO2006114520A3 (en) * 2005-04-26 2007-03-01 Aventis Pharma Sa Substituted pyrrolo-pyridines, composition containing them, method for their producing and use thereof
JP2008539211A (en) * 2005-04-26 2008-11-13 アバンテイス・フアルマ・エス・アー Substituted pyrrolopyridines, compositions containing substituted pyrrolopyridines, methods for their preparation and uses thereof
EA012983B1 (en) * 2005-04-26 2010-02-26 Авентис Фарма С.А. Substituted pyrrolo-pyridines, method for their producing and use thereof
WO2006114520A2 (en) * 2005-04-26 2006-11-02 Aventis Pharma S.A. Substituted pyrrolo-pyridines, composition containing them, method for their producing and use thereof
FR2884821A1 (en) * 2005-04-26 2006-10-27 Aventis Pharma Sa New pyrrolo pyridine compounds are kinase inhibitors useful as an inhibiting agent for kinase-catalyzed reaction and for the manufacture of a drug to treat cancer
US7947706B2 (en) 2005-04-26 2011-05-24 Sanofi-Aventis Deutschland Gmbh Substituted pyrrolopyridines, compositions containing them, manufacturing process therefor and use thereof
US7846941B2 (en) 2005-05-17 2010-12-07 Plexxikon, Inc. Compounds modulating c-kit and c-fms activity and uses therefor
US7863288B2 (en) 2005-06-22 2011-01-04 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
US7645769B2 (en) 2005-08-05 2010-01-12 Eisai R & D Management Co., Ltd. Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation
WO2007106236A3 (en) * 2006-02-27 2007-12-21 Sgx Pharmaceuticals Inc Pyrrolo-pyridine kinase modulators
WO2007106236A2 (en) * 2006-02-27 2007-09-20 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US20090312355A1 (en) * 2006-08-03 2009-12-17 Trustees Of Tufts College Non-Flushing Niacin Analogues, and Methods of Use Thereof
JP2009545616A (en) * 2006-08-03 2009-12-24 トラスティーズ オブ タフツ カレッジ Flushing-free niacin analogs and their use
US8889720B2 (en) 2006-08-03 2014-11-18 Trustees Of Tufts College Non-flushing niacin analogues, and methods of use thereof
US8377971B2 (en) * 2006-08-03 2013-02-19 Trustees Of Tufts College Non-flushing niacin analogues, and methods of use thereof
US9511060B2 (en) 2006-08-03 2016-12-06 Trustees Of Tufts College Non-flushing niacin analogues, and methods of use thereof
US9193708B2 (en) 2006-08-03 2015-11-24 Trustees Of Tufts College Non-flushing niacin analogues, and methods of use thereof
US9487515B2 (en) 2006-11-22 2016-11-08 Plexxikon Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US9169250B2 (en) 2006-11-22 2015-10-27 Plexxikon Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US7893075B2 (en) 2006-11-22 2011-02-22 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US9469640B2 (en) 2007-07-17 2016-10-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US10426760B2 (en) 2007-07-17 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9844539B2 (en) 2007-07-17 2017-12-19 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US8841304B2 (en) 2008-01-08 2014-09-23 Array Biopharma, Inc. Pyrrolopyridines as kinase inhibitors
WO2009089352A1 (en) 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
US8372842B2 (en) 2008-01-09 2013-02-12 Array Biopharma Inc. Pyrazolopyridines as kinase inhibitors
WO2009140320A1 (en) * 2008-05-13 2009-11-19 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
US8758830B2 (en) 2008-05-13 2014-06-24 Array Biopharma, Inc. Pyrrolopyridines as kinase inhibitors
JP2011520896A (en) * 2008-05-13 2011-07-21 アレイ バイオファーマ、インコーポレイテッド Pyrrolopyridine as a kinase inhibitor
KR20140093266A (en) * 2008-05-13 2014-07-25 어레이 바이오파마 인크. Pyrrolopyridines as kinase inhibitors
KR20110008102A (en) * 2008-05-13 2011-01-25 어레이 바이오파마 인크. Pyrrolopyridines as kinase inhibitors
CN109942575A (en) * 2008-05-13 2019-06-28 阵列生物制药公司 Pyrrolopyridine as kinase inhibitor
US9969727B2 (en) 2008-05-13 2018-05-15 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
US8981085B2 (en) 2008-05-13 2015-03-17 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
EP2990407A1 (en) 2008-05-13 2016-03-02 Array Biopharma, Inc. Pyrrolopyridines as kinase inhibitors
CN104926810A (en) * 2008-05-13 2015-09-23 阵列生物制药公司 Pyrrolopyridines As Kinase Inhibitors
TWI458727B (en) * 2008-05-13 2014-11-01 Array Biopharma Inc Pyrrolopyridines as kinase inhibitors
US8545897B2 (en) 2008-05-13 2013-10-01 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
AU2009246402B2 (en) * 2008-05-13 2013-05-23 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
TWI554512B (en) * 2008-05-13 2016-10-21 亞雷生物製藥股份有限公司 Pyrrolopyridines as kinase inhibitors
US8178131B2 (en) 2008-05-13 2012-05-15 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
KR101657856B1 (en) 2008-05-13 2016-09-19 어레이 바이오파마 인크. Pyrrolopyridines as kinase inhibitors
AU2013218743B2 (en) * 2008-05-13 2016-04-28 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
US9365568B2 (en) 2008-05-13 2016-06-14 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
KR101643426B1 (en) 2008-05-13 2016-07-27 어레이 바이오파마 인크. Pyrrolopyridines as kinase inhibitors
WO2010016490A1 (en) 2008-08-05 2010-02-11 第一三共株式会社 Imidazopyridin-2-on derivative
US9447089B2 (en) 2009-04-03 2016-09-20 Plexxikon Inc. Compositions and uses thereof
US9663517B2 (en) 2009-04-03 2017-05-30 Plexxikon Inc. Compositions and uses thereof
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
JP2012523435A (en) * 2009-04-11 2012-10-04 アレイ バイオファーマ、インコーポレイテッド Checkpoint kinase 1 inhibitor for enhancing DNA damaging factors
US9155726B2 (en) 2009-04-11 2015-10-13 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
US9096593B2 (en) 2009-11-06 2015-08-04 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9370567B2 (en) 2010-11-16 2016-06-21 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and WEE 1 kinase inhibitors
US10434094B2 (en) 2010-11-16 2019-10-08 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
WO2012074754A1 (en) 2010-11-16 2012-06-07 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
US11337976B2 (en) 2011-02-07 2022-05-24 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US8865735B2 (en) 2011-02-21 2014-10-21 Hoffman-La Roche Inc. Solid forms of a pharmaceutically active substance
US10000481B2 (en) 2012-01-30 2018-06-19 Vernalis (R&D) Limited 1H-pyrrolo[2,3-B] pyridine derivatives and their use as kinase inhibitors
JP2015505555A (en) * 2012-01-30 2015-02-23 ヴァーナリス （アールアンドディー） リミテッドＶｅｒｎａｌｉｓ （Ｒ＆Ｄ） Ｌｉｍｉｔｅｄ 1H-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitors
US10889582B2 (en) 2012-01-30 2021-01-12 Vernalis (R&D) Limited 1H-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitors
US9695169B2 (en) 2012-05-31 2017-07-04 Plexxikon Inc. Synthesis of heterocyclic compounds
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
RU2672725C2 (en) * 2013-08-22 2018-11-19 Дженентек, Инк. Method of preparing compound
US10329288B2 (en) 2013-08-22 2019-06-25 Genentech, Inc. Process for preparing a compound
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
US11618749B2 (en) 2018-07-03 2023-04-04 Ifm Due, Inc. Compounds and compositions for treating conditions associated with STING activity
CN109942574A (en) * 2019-01-11 2019-06-28 成都阿奇生物医药科技有限公司 Its surprise is for Buddhist nun and its preparation method and application
CN109942574B (en) * 2019-01-11 2022-04-01 成都阿奇生物医药科技有限公司 Tianqitinib and preparation method and application thereof
WO2020150417A3 (en) * 2019-01-17 2020-08-27 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2020150417A2 (en) 2019-01-17 2020-07-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2022015977A1 (en) * 2020-07-15 2022-01-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2022015979A1 (en) 2020-07-15 2022-01-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2022150543A1 (en) 2021-01-08 2022-07-14 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2022237922A1 (en) * 2021-05-10 2022-11-17 Fakultni Nemocnice Hradec Kralove Antitumor compounds based on nitrogen heterocycles and use thereof as medicaments
CZ309579B6 (en) * 2021-05-10 2023-04-26 Fakultní nemocnice Hradec Králové Antitumor compounds based on nitrogen heterocycles, their use as drugs and pharmaceutical preparations containing them

Similar Documents

Publication Publication Date Title
WO2003028724A1 (en) Chk1 kinase inhibitors
AU2004276337B2 (en) Inhibitors of histone deacetylase
DK2455381T5 (en) Triazolopyridinforbindelse and its effect as an inhibitor of prolyl hydroxylase and induce erythropoietin production by
CA2409743C (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
ES2835553T3 (en) Indazole Inhibitors of the Wnt Signaling Pathway and Their Therapeutic Uses
AU2014275643B2 (en) Heterocyclic derivatives and use thereof
US6403633B2 (en) Heteroaryl amidines, methylamidines and guanidines, and use thereof as protease inhibitors
JP7175888B2 (en) Piperazine Derivatives as Selective HDAC1,2 Inhibitors
JP6042060B2 (en) Pyrazoloquinolinone derivatives, their preparation and therapeutic use
AU2013366898B2 (en) Halogen-substituted heterocyclic compound
WO1999037622A1 (en) Nitrogenous heterocyclic derivatives and medicine thereof
JP2011504505A (en) Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders
WO2012037108A1 (en) Aminoquinoline derivatives as antiviral agents
WO2003029241A1 (en) Chk1 kinase inhibitors
KR20020027625A (en) Amino-triazolopyridine derivatives
CN103588704A (en) Inhibitors of focal adhesion kinase
EP2161271A1 (en) Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl
TW201010977A (en) Amide compound
JP6636153B2 (en) Pyridine and their use in cancer treatment
JP2009023986A (en) Biaryl derivative as anticancer agent
WO2009107391A1 (en) Compound having 6-membered aromatic ring
CA2578168A1 (en) 2-phenylpyridine derivative
CN101400678A (en) Thiophene-carboxamides useful as inhibitors of protein kinases
NZ534821A (en) Pyranones useful as ATM inhibitors
US20160311772A1 (en) Compounds as tnik, ikkepsilon and tbk1 inhibitors and pharmaceutical composition comprising same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ PH PL PT RO SD SE SG SI SK SL TJ TM TR TT TZ UG US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP